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Zusammenfassung
I
Zusammenfassung
Die paroxysmale nächtlicher Hämoglobinurie (PNH) ist ein erworbener
klonale Defekt von hämatopoietischen Stammzellen charakterisiert durch die
Defizienz Glycosylphosphatidylinositol (GPI)-verankerten Oberflächen-
proteine auf den peripheren Blutzellen. Diese Proteine schließen
komplementregulatorischen Molekülen CD55 und CD59 ein, und das Fehlen
an ihnen erklärt die Empfindlichkeit der Erythrozyten vom PNH Patienten
gegenüber der Komplement-vermittelten Lyse, wodurch eine intravasale
Hämolyse bewirkt wird. Dieser Defekt wurde Mutationen innerhalb des PIG-
A Gens zugeschrieben, das für ein in GPI-Anker-Biosynthese beteiligtes
Protein kodiert.
Jedoch ist der Mechanismus, durch den die GPI-defizienten Stammzellen
innerhalb des Knochenmarks expandieren noch nicht geklärt worden.
Mutationen in PIG-A Gen sind für die Entwicklung der PNH nicht
ausreichend, da sie durch der GPI-Defizienz allein nicht expandieren. Deshalb
sind zusätzliche Veränderungen wie Alterationen wahrscheinlich, die zur
klonalen Expansion von GPI-defizienten Knochenmark Stammzellen bei der
PNH führen.
Um die molekulare Grundlage der klonalen Expansion bei der PNH zu
analysieren, identifizierten wir mehrere differentiell exprimierte Gene im
Vergleich normaler und GPI-defizienter Zellen von PNH Patienten durch
Anwendung zweier divergierender Ansätze: RNA Fingerprinting und cDNA
array-Hybridisierung. Aus eine Serie von 26 differentiell exprimierten Genen
haben wir 2 Kandidaten (EGR-1 und TAXREB107) für weitere Untersuchung
ausgewählt, da sie eine ausgeprägtere Alteration des Expressionsniveaus
aufweisen. Außerdem wurde ihnen bereits eine Rolle in Regulierung der
Hämatopoese zugeschrieben. EGR-1 ist hochreguliert in Granulozyten aller
bis jetzt analysierten PNH Patienten. Im Gegensatz dazu wurde eine
signifikante Hochregulation von TAXREB107 nur in einigen unserer PNH
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Patienten beobachtet, die die PNH im Verlauf einer aplastischen Anämie
entwickelt haben. In weiteren Analysen konnten wir ein mögliches
sekundäres Ereignis als Ursache der beobachteten Überexpression
ausschließen. Außerdem ist ein ähnliches Expressionsniveau in Fällen anderer
klonaler Erkrankungen wie MPS und MDS identifiziert worden. Um den
Hintergrund der entdeckten Änderung des Expressions Niveaus zu
analysieren, haben wir die chromosomale und molekulare Organisation des
EGR-1 Gens und seiner Transkripte untersucht. Wir entdeckten keine
Genamplifikation und keine Änderungen der primären Struktur im Bereich
der Promoterregion. Jedoch offenbarten sich einige Mutationen der
Kodierenden Region des EGR-1 Gens im Bereich der Zink-Finger Domänen.
Die indentifizierten Mutationen im sensiblen Funktionsbereich könnten zur
Hochregulation der Gen Expression beitragen oder sogar für sie
verantwortlich sein.
Zusammengefaßt zeigen unsere Daten, daß zusätzliche genetische
Änderungen neben Mutationen in PIG-A bei den GPI-defiziente Zellen von
PNH-Patienten vorhanden sind. Außerdem könnten solche genetischen
Änderungen in Zellaktivierungs-Repertoire zur klonalen Expansion von GPI-
defizienten Zellen bei der PNH beitragen.
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Summary
Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired clonal defect of
hematopoietic stem cells characterized by appearance of peripheral blood
cells deficient in glycosylphosphatidylinositol (GPI)-anchored surface
proteins. These proteins include complement inhibitors CD55 and CD59, and
lack of them explains the hypersensitivity to complement-mediated lysis of
red cells in PNH patients, resulting in intravascular hemolysis. This defect
could be attributed to mutations within the PIG-A gene encoding for a protein
involved in GPI-anchor biosynthesis.
However, the mechanism enabling the GPI-deficient stem cell in PNH to
expand within the bone marrow and contribute considerably to the
hematopoiesis has not been clarified yet, because PIG-A gene mutations are
not sufficient for the development of PNH, and GPI-deficient cells do not
expand by themselves. Therefore, a second event is very likely, such as
additional genetic alterations, leading to clonal expansion of GPI-deficient
bone marrow stem cells in PNH.
In order to elucidate the molecular basis of clonal expansion in PNH we
identified several genes differentially expressed in normal and GPI-deficient
cells of PNH patients by combination of two divergent approaches: RNA
fingerprinting and cDNA array hybridization. From a set of 26 differentially
expressed genes, we have chosen 2 candidates (EGR-1 and TAXREB107) for
further investigation according to their more pronounced alteration of
expression level and their previously described role in regulation of
hematopoiesis. EGR-1 is upregulated in granulocytes of all PNH patients
analyzed so far. In contrast, significant upregulation of TAXREB107 is present
only in some of our PNH patients, who developed PNH after aplastic anemia.
Further analysis confirmed overexpression of these genes in PNH and
excluded a possible secondary event character of the observed
overexpression. Moreover, similar level of expression in cases of other clonal
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diseases such as MPS and MDS has been identified. In order to analyze
detected change in expression level, we studied chromosomal and molecular
organization of EGR-1 gene and transcript. We detected no gene
amplification, no changes in primary structure of promoter area. However,
we revealed some mutations in the coding region of EGR-1 gene
corresponding to the area encoding for zinc-finger domains. It might be that
these identified molecular alterations can contribute to or even be responsible
for the upregulation of EGR-1 gene expression.
Taken together, our data indicate that additional genetic alterations apart
from PIG-A mutations are present in PNH. In addition, such genetic changes
in cellular activating repertoire could contribute to clonal expansion of GPI-
deficient cells in PNH. 
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Introduction
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1. Introduction
1.1. Paroxysmal nocturnal hemoglobinuria
1.1.1. Clinical appearance
Paroxysmal nocturnal hemoglobinuria (PNH) was first described as a distinct
clinical entity by Paul Strübing in 1882 (Strübung 1882). Through careful
observation of clinical symptoms he recognized PNH as distinct from other
hemolytic anemias and, in particular, being different from the hemolytic
anemia due to cold hemolysis which was commonly found in cases of syphilis
at that time. He noted that the hemolysis was intravascular and reasoned that
it might be a result of intrinsic abnormality of the red cell membrane. About
50 years later, Ham demonstrated that the hemolysis in PNH is due to
abnormal sensitivity of red cells to complement (Ham and Dingle 1939),
which can be tested in vitro by acidification of autologous plasma activating
especially the alternative complement cascade.
Paroxysmal nocturnal hemoglobinuria is an acquired blood disorder; its
incidence is estimated at about one case in scores of hundred thousands of
persons (Luzzatto et al. 1997; Bessler and Hillmen 1998). The diagnosis is
most frequently in adults of age 30-50; however, PNH also occurs in the
oldery and in children as young as 0,8 year (Ware et al. 1991; Hillmen et al.
1995; Socie et al. 1996). Patients with PNH classically have hemoglobinuria
caused by intravascular hemolysis, suffer from thrombosis and have
complications of bone marrow failure (Dacie and Lewis 1972). The severity of
symptoms often varies, which often delays diagnosis.
The name of the disease was coined from hemoglobinuria, the passage of red
or dark brown urine, although this symptom is found initially in only a
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quarter of patients. The extent of hemolysis and the degree of anemia are
highly variable from patient to patient. 
Hemoglobinuria in patients with PNH is caused by intravascular lysis of red
cells that are abnormally sensitive to complement attack. However, not all red
cells have this increased sensitivity, since a variable proportion of them is
normal. At the same time a proportion of other blood cells displays the same
defect of the abnormal red cells, namely deficiency of all proteins bound to
the cell membrane by a glycosylphosphatidylinositol (GPI)-anchor (Davitz et
al. 1986). The residual normal blood cell population is often reduced in
number, suggesting that it is derived from failing bone marrow. Many
patients with PNH have evidence of deficient hematopoiesis, and the degree
of bone marrow failure varies from subclinical cytopenia to the development
of severe aplastic anemia (AA). Conversely, PNH has also been described in
patients affected by aplastic anemia (Dameshek 1967; Lewis and Dacie 1967).
The main causes of morbidity and mortality in PNH are venous thrombosis,
which is appeared to occur in 40% of patients; and the results of intravascular
hemolysis, which are associated with hemoglobinuria, abdominal pain and,
not frequently, dysphagia. The main causes of death due to PNH are venous
thrombosis and complications from progressive pancytopenia (Hillmen et al.
1995; Socie et al. 1996).
1.1.2. The cellular phenotype of PNH-cells
The hallmark of PNH blood cells in that they are deficient in all proteins that
use a glycosylphosphatidylinositol (GPI)-anchor molecule (Davitz et al. 1986)
(Figure 1). Today, at least 27 different GPI-linked proteins are known to be
deficient on PNH blood cells. The lack of 2 of those molecules is sufficient for
the diagnosis of PNH.
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Figure 1: Structure of the GPI-anchor.
GPI-linked proteins on hematopoietic cells perform a multitude of functions.
They serve as ecto-enzymes, accessory molecules for growth receptors,
complement inhibitors, or adhesion molecules. CD55 (or DAF – decay
accelerating factor) and CD59 (or MIRL – membrane inhibitor of reactive
lysis) are complement regulatory proteins that inhibit complement activation
on the cell surface (Nicholson-Weller et al. 1983; Holguin et al. 1989). The lack
of these 2 proteins on red cells is responsible for their increased sensitivity
toward complement and thus intravascular hemolysis and hemoglobinuria in
PNH. Based on this observation the Ham test of PNH diagnosis was
developed. More recently, analysis of blood cells by flow cytometry with
monoclonal antibodies to GPI-linked surface molecules has been used for the
diagnosis of PNH. When performed on granulocytes and erythrocytes this
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type of analysis has a high sensitivity and is the preferable diagnostic test for
the current time (Hall and Rosse 1996).
The biological role of GPI anchor is not fully understood. GPI-linked proteins
can be released by specific phospholipases (GPI-PLS and GPI-PLD) (Low
2000). In thrypanosomes, GPI-PLC-controlled release of the variant specific
glycoprotein, the main coat protein, enables the parasite to evade the host
immune response. However, the functional role of GPI-PLC and GPI-PLD in
human tissues remains elusive. Good lateral mobility, which is another
characteristic of GPI-anchor, is likely to be relevant for many GPI-linked
proteins that require the clustering of GPI-anchor molecules in the association
with microdomains, or “rafts”, enriched in glycophospholipids and
cholesterol. The association with microdomains contributes to the specific
surface distribution of GPI-linked proteins and aids in the recruitment of
accessory molecules for the cell signaling (Horejsi et al. 1998).
GPI-anchored proteins are widely distributed among cell surface proteins in
eukaryotic organisms and are highly conserved in all eukaryotic cells. In all
species, the GPI anchor shares a common core region consisting of
ethanolamine phosphate, 3 mannoses, glucosamine and inositol.
1.1.3. Complement-mediated hemolysis
For erythrocytes the function of two GPI-anchored proteins ― CD55 and
CD59 ― is very important. They play a role in protection of the cell against
lysis by activated complement, especially the alternative complement cascade.
CD55 (DAF) destabilizes and inhibits the formation of C3-convertase.
However, the most significant protective molecule is evidently CD59 (MIRL),
a 20-kDa membrane glycoprotein discovered in 1989. CD59 designates its
status as a cell-surface marker recognized by specific antibody. It binds to the
C8 component of complement, thereby preventing C9 from fully binding, an
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event that would initiate the polymerization of C9 into the toruslike structure
required for the complement system to make a hole in the cellular membrane
(Figure 2).
Figure 2: Schematic representation of complement-mediated lysis of GPI-anchor
deficient erythrocytes in PNH. A: On the surface of normal cell CD55 inhibits the
formation or destabilizes the C3 convertase and CD59 protects the membrane from
attack by the C5-C9 complex. B: On the surface of GPI-deficient erythrocytes in PNH
both proteins are missing. Therefore, membrane attack complex can be formed what
leads to membrane rupture and cell lysis.
1.1.4. GPI-anchor biosynthesis and PIG-A gene
Biochemical analysis of GPI-anchor biosynthesis in cell line obtained from
patients with PNH shown that the mature GPI anchor is not formed. In all cell
lines tested, the block in the biosynthetic pathways always occurs in the first
step when uridine diphospho-N-acetylglucosamine (UDP-Glc-NAc) is
C3
transmembrane
proteins
C9
C3-convertasePoly-C9
PNH
A B
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transferred to phosphatidylinositol to form N-acetylglucosaminyl-
phosphatidylinositol (Glc-NAc-PI) (Armstrong et al. 1992). At least 6 gene
products are involved in this particular step; 4 of which are essential for GPI-
anchor biosynthesis (Watanabe et al. 2000).
During the time when genes involved in GPI-anchor biosynthesis were
unknown, cell lines deficient in GPI-linked proteins were obtained by in vitro
mutagenesis. The mutant cell lines were grouped into 10 different
complementation classes by using somatic cell fusion experiments. Fusion of
cell lines derived from PNH patients with the mutant cell lines showed that
all PNH cells tested belonged to complementation class A. This suggested
that PNH cells and mutant cell lines from the complementation class A have
the genetic defect (Armstrong et al. 1992; Takahashi et al. 1993).
In 1993, the gene defective in cell lines from complementation group A was
cloned and accordingly was named PIG-A, which stands for
phospatidyinositol glycan complementation class A (Miyata et al. 1993).
When transfected into GPI-deficient cells from PNH patients, the PIG-A
complementary DNA restored the expression of GPI-linked proteins on the
cell surface (Takeda et al. 1993; Bessler et al. 1994). After the cloning of the
PIG-A gene, mutations were identified in blood cells from patients with PNH,
which finally confirmed that the PIG-A gene is the gene mutated in PNH
(Miyata et al. 1994; Ostendorf et al. 1995; Luzzatto and Nafa 2000).
The PIG-A gene is approximately 17 kilobases (kb) long and has 6 exons. Exon
1 is noncoding, and exon 2 accommodates almost half of the PIG-A gene
coding region (Bessler et al. 1994; Iida et al. 1994). Exon 5 contains sequences
that have homology to the Glc-NAc-transferase of Salmonella typhimurium
and glycosyltransferases in plants and thus might be the binding site of UDP-
GlcNAc (Bessler et al. 1994). Exon 6 contains the transmembrane domain of
PIG-A. The PIGA cDNA consists of 3589 base pairs (bp) with an open reading
frame of 1452 bp encoding a putative protein of 484 amino acids (Miyata et al.
1994). The PIG-A gene maps to the short arm of the X chromosome at Xp22.1.
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A nonfunctional processed pseudogene has been mapped to 12p21 (Bessler et
al. 1994).
The PIG-A protein locates to the endoplasmic reticulum (ER). The amino
terminus of the protein lies on the cytoplasmic side of the ER where the initial
step of GPI-anchor synthesis takes place. The PIG-A protein is a subunit of the
UDP-GlcNAc:PI-α-1, 6-GlcNAc-transferase complex, which is formed by at
least 6 different protein subunits (PIG-A, PIG-H, PIG-C, GPI-1, dolichol-
phosphate-mannose synthase (DPM-2), and PIG-P). PIG-A binds to PIG-H,
GPI-1, DPM-2 and PIG-P, but is not stable associated with PIG-C (Hong et al.
1999; Watanabe et al. 2000). PIG-A, like PIG-H, PIG-C and PIG-P, is essential
for the enzymatic activity of the glycosyltransferase. In contrast, GPI-1 and
DPM-2 are not essential components of the transferase but enhance its activity
(Watanabe et al. 2000).
To date, over 180 mutations have been published to be found in GPI-deficient
blood cells from patients with PNH (Luzzatto and Nafa 2000). The majority of
PIG-A gene mutations are frame shift mutations that predict an inactive PIG-
A protein and a loss of glycosyltransferase activity. The mutations are
distributed over the entire coding region with no obvious clustering. Only 16
mutations out of 174 were reported to be found in more than 1 PNH patient
(Nishimura et al. 1999). There is some clustering of missense mutations over
the coding region of exon 2. Some of these missense mutations have been
shown to cause only a partial deficiency in GPI-linked proteins on the cell
surface, indicating that the mutant glycosyltransferase has some residual
activity (Bessler et al. 1994). One mutation (nucleotide 55 C→T, Ava I
polymorphism) is not associated with the loss of GPI-linked proteins on the
cell surface and, in contrast to all other PIG-A mutations, it is inherited in
Mendelian fashion. All other mutations are presented only in the patient’s
GPI-deficient cells, but not in the patient’s normal cells, which is consistent
with the somatic nature of the PIG-A mutation and the clinical fact that PNH
is an acquired disease.
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The cloning of the PIGA gene and identified mutations have considerable
impact on our understanding of the pathogenesis of PNH. The mutations
explain the deficiency of GPI-linked proteins on the cell surface and the
clinical symptoms of intravascular hemolysis and hemoglobinuria (Figure 3).
Figure 3: PIG-A, GPI-anchors, GPI-anchored proteins and PNH. PIG-A is a protein
encoded by the X-linked gene PIG-A. PIG-A is a member of multi-subunit enzymatic
complex which catalyzes in the endoplasmic reticulum (ER) the first step in the
biosynthesis of GPI: the addition of acetylglucosamine (GlcN) to
phosphatidylinositol (inositol-P). The synthesis of the GPI-anchor is completed by
the serial addition of a glycan moiety consisting of three mannose molecules and a
molecule of phosphoethanolamine (Eth-P), to which, through a transpeptidation
reaction, proteins with appropriate carboxy-terminal amino acid motif are covalently
attached. The GPI-protein becomes “anchored“ to the lipid bilayer through GPI. In
PNH, PIG-A has undergone somatic mutations within one or few HSCs, which are
clonaly expanded. As a result, very few GPI-anchor molecules is synthesized, or
none at all, leading to subsequent severe deficiency of GPI-linked proteins on the
surface of the mutated HSCs and their progeny (from (Karadimitris and Luzzatto
2001)).
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PIG-A gene is localized on the X chromosome and, therefore, it is subject to X
chromosome inactivation in females (Keller et al. 1999). Therefore, a single
mutation can cause the loss of GPI-linked proteins on both male and female
somatic cells. Thus, in males the inactivation of the one PIG-A allele is
sufficient to cause the loss of GPI-linked proteins on the cell surface. In
females the inactivation of PIG-A allele when it is on the active X
chromosome will lead to the loss of GPI-linked proteins on the cell surface
(due to random X-inactivation this is expected to occur in about half of the
cells). Therefore, in both male and female cells a single mutation (1 hit) is
sufficient to inactivate PIG-A protein function and cause the loss of GPI-
linked proteins on the cell surface. Moreover, all other genes involved in the
GPI-anchor biosynthesis are autosomal. Therefore, the loss of GPI-anchored
proteins would thus require 2 mutations, an event that is extremely unlikely
to occur.
1.1.5. PNH as a consequence of the clonal expansion of GPI-deficient cells
1.1.5.1. PNH stem cells have an intrinsic growth advantage but PIG-A gene
mutation by itself does not provide it
The clonal character of the GPI-deficient cells of a PNH patient has been
initially shown by polymorphism analysis of the glucose-6-phosphat-
dehydrogenase in the complement sensitive erythrocytes (Oni et al. 1970).
Since in PNH GPI-deficient cells always coexist with at least a small fraction
of cells with normal phenotype the hypothesis that PNH is an acquired clonal
defect has been established (Rotoli et al. 1984). Recent studies of the topic
show that PNH is not necessarily a monoclonal illness. At least in some
patients several different clones with different PIG-A mutations contribute to
the GPI-deficient cell fraction. Up to 4 different PIG-A gene mutations have
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been identified to coexist in the bone marrow from PNH patients and give
rise to independent PNH clones. Hereby, PNH rather needs to be understood
as oligoclonal disease (Bessler et al. 1994; Parker 1996).
In colony-forming assay has been observed decreased hematopoietic capacity
for bone marrow cells of PNH patients measured by CFU-E (Rotoli et al.
1982). This observation was the basis for the hypothesis that GPI-deficient
cells shows not absolute but a relative growth advantage in the bone marrow
of the PNH patients (Schubert et al. 1994; Luzzatto and Bessler 1996). More
recently CD34+ cell numbers and the number in vitro cultivated long-term-
culture-initiating-cells (LTCIC) from the bone marrow and the peripheral
blood of normal donors and PNH patients were compared (Maciejewski et al.
1997). A clear difference of cell numbers for normal donors and PNH patients
was observed, but not in the LTCIC formation from CD34+CD59+ and
CD34+CD59- cells of the same PNH patient.
To check these theories further, there have been done some experiments in
order to generate PIG-A-knockout mice. However, PIG-A-knockout animals
were not capable to survive, because some of GPI-anchored surface
molecules, particularly N-CAM, are essential for the neural development of
mammalian (Schubert et al. 1994). Therefore, as a model of PNH a chimeric
PIG-A knockout mouse was developed. The relative amount of GPI-deficient
cells decreases in such chimeric PIG-A-knockout mice at a prolonged
observation period (Kawagoe et al. 1996; Rosti et al. 1997).
In addition, GPI-deficient clones containing PIG-A mutations have even been
detected in normal donors at trace amounts and without a tendency to
expand (Luzzatto and Bessler 1996; Araten et al. 1999). 
Taken together, these data suggest an intrinsic growth advantage of the PNH
stem cell dominating the bone marrow and indicate that a PIG-A gene
mutation by itself neither provides such an intrinsic growth advantage nor
does it cause bone marrow failure. Indeed, in a neutral environment, the PIG-
A- hematopoiesis is rather indifferent.
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At the moment it is not clear why GPI-deficient cells in PNH are able to
expand. Three hypotheses were offered as an attempt to explain such a clonal
expansion despite the growth and activation disadvantage associated with
lack of GPI-linked cell surface proteins.
1.1.5.2. Somatic cell selection and immunological attack escape in PNH 
The first of these hypotheses is a clonal selection mediated by an
immunological attack against the bone marrow stem cells from which GPI-
deficient cells escape by an increased resistance to the action of cytotoxic cells
(Young 1992). This hypothesis is based on the observation that within the
aplastic anemia complete remission can be achieved by immunosuppressive
therapy (Cosimi et al. 1982; Gluckman et al. 1982; Frickhofen et al. 1991). In
addition, an expansion of GPI-deficient cells was observed for patients
without hematological system illness, which were treated with the
monoclonal antibody Campath-1H against GPI-linked CD52 (Hertenstein et
al. 1995). The cytotoxic effect of the rat's antibody caused a selection in favor
GPI-deficient lymphocytes and monocytes within patients, so that the GPI-
deficient cells can expand.
The mechanism of bone marrow failure is still poorly understood but is
believed to be immune mediated. Hypothesized escape mechanism of PNH
cells toward this immune attack is unclear but is presumed to be mediated by
one or more GPI-linked cell surface antigens. Recent reviews propose a
variety of models that might explain the escape of PNH cells, but so far a clear
implication of the role of any GPI-linked protein is lacking. 
According to the immune selection theory proposed by the group of
L.Luzzatto (Bessler et al. 1994) autoimmunity is primarily directed against
either the GPI-anchor or a GPI-linked protein. Immune selection theory is
supported by observation of a skewed T-cell repertoire in PNH patients that
indicates the presence of specific T-cell clones recognizing the GPI-anchor or a
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GPI-linked protein (Karadimitris et al. 2000). However, normal and GPI-
deficient cells turned out to be equally sensitive to allogenic T lymphocytes
(Karadimitris et al. 2000).
Recently 2 proteins, at least one of which is GPI-linked, have been identified
in mice that may directly connect the lack of GPI-linked proteins to the
immune escape mechanism. Both proteins, retinoic acid early inducible (REA-
1) and H-60, bind the NKG2D receptor of natural killer (NK) lymphocytes
(NK cells). Ligand binding of NKG2D leads to NK cell activation and NK-
mediated cell death mainly by the perforin-granzyme pathway. Both ligands
are relatively restricted in expression on normal adult mouse tissues but are
upregulated on stressed cells. Thus, the human REA-1 and H-60 homologues
(ULBOs, UL16 binding proteins) might be interesting candidate molecules
that when expressed on hematopoietic stem cells in the early stages of bone
marrow failure activate NK cells to kill the cell carrying them. In contrast,
PNH stem cells fail to express these ligands and thus escape immune
surveillance by NK cells.
1.1.5.3. Resistance to apoptosis
As an alternative to the immune escape it has been suggested that GPI-
deficiency itself leads to an increased resistance to apoptosis (Brodsky et al.
1997). An increased rate of apoptosis has been observed in patients with
aplastic anemia or myelodysplastic syndrome. If GPI-deficient cells only by
absence of GPI-linked surface molecules would exhibit such a resistance
clonal dominance of the GPI-deficient clone would result in the context of AA
or MDS. However, such a resistance just due to GPI-deficiency could not be
reproduced by other groups (Ware et al. 1998; Bastisch et al. 2000).
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1.1.5.4. Appearance of additional alterations in cellular activating repertoire is
necessary for PNH development 
The third hypothesis based on the observation that paroxysmal nocturnal
hemoglobinuria (PNH), aplastic anemia (AA) and myelodysplastic syndrome
(MDS) are related diseases (Marsh and Geary 1991; Young and Maciejewski
2000). Therefore, clonal dominance can be caused by appearance of additional
mutations in cellular activating genes in different parts of the bone marrow.
This hypothesis is confirmed by the observation that early hematopoietic
progenitor cells of PNH patients can grow in vitro without addition of
exogenous cytokines in contrast to those of healthy donors (Issaragrisil et al.
1986). In addition, preferential hematopoiesis of PNH clone engrafted in SCID
mice has been observed (Iwamoto et al. 1996). 
Moreover, GPI-deficient cells characteristic for PNH are very often detectable
in AA and MDS (Yamaguchi et al. 2000). It has been observed that genetic
instability is involved in the pathogenesis of these hematopoietic stem cell
disorders. Investigation in vivo mutation frequencies suggest that not only
PIG-A but also other genes are hypermutable in PNH, AA and MDS, and that
mutagenic pressure and/or gene instability can contribute to the pathogenesis
of these disorders (Hattori et al. 1997).
Therefore, clonal expansion of GPI-deficient cells in PNH might be caused by
additional gene alterations.
Which of these hypotheses will turn out at the end to be valid is not currently
clear. It is also possible that a combination of both mechanisms leads to the
expansion of the GPI-deficient clone. Besides, the genetic changes in the
activation program of the cells could themselves lead to a secondary
immunological reaction.
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1.2. Aim of the study
Paroxysmal nocturnal hemoglobinuria is an acquired clonal defect of
hematopoietic stem cells characterized by deficiency in GPI-anchored surface
proteins. It is not yet known how GPI-deficient stem cells are able to expand
within the bone marrow and contribute considerably to hematopoiesis. In
PNH as well as in AA and MDS, genetic instability and increased mutation
frequency have been detected. Therefore, a second event is very likely, such
as additional mutations or differential gene regulation, leading to clonal
expansion of GPI-deficient bone marrow stem cells in PNH. 
The aim of the study was to investigate molecular bases of clonal expansion in
PNH and identify genes differentially expressed in normal and GPI-deficient
cells of PNH patients, analyze the genes found, confirm their differential
expression and characterize it in PNH.
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2. Materials and Methods
2.1. Materials
2.1.1. Chemicals and reagents
2.1.1.1. Fine chemicals
Chemicals and reagents were obtained from the companies Amersham,
AppliChem, Becton-Dickinson, Biomol, Boehringer Mannheim, Gibco BRL,
Difco, Fluka, Genomed, Hartmann, ICN, Merck, New England Biolabs, Pierce,
Qiagen, Riedel de Haen, Roth, Serva, Sigma, Stratagene, Invitrogen. Other
materials were obtained from Beckmann, Costar, Eppendorf, Eurogentec,
Falcon, Kodak, Gilson, Sarstedt, Schleicher+Schuell and Whatman. Solutions
for the cell culture were provided by Seromed/Biochrom.
2.1.1.2. Radiochemicals
[α32P] dATP (3000 Ci/mmol) Amersham, Braunschweig
2.1.2. Buffers and solutions
2.1.2.1 Buffers
TAE-buffer 40 mM Tris-Acetat
1 mM EDTA
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10x TBE buffer 108 g Tris base (890 mM)
55 g boric acid (890 mM)
40 ml 0,5 M EDTA, pH 8,0
TE-buffer 10 mM Tris-HCl
1 mM EDTA
pH 7,4
20x SSC buffer 3 M NaCl
0,3 M Na Citrate
adj. with 1 M HCl to pH 7,0
5x MOPS buffer 0,1 M MOPS (pH 7,0)
40 mM sodium acetate
5 mM EDTA (pH 8,0)
store up to 3 months at 4°C
PBS 140 mM NaCl
2,6 mM KCl
2 mM Na2HPO4
1,45 mM KH2PO4
6x gel loading buffer 1 0,25% Bromophenol blue
0,25% Xylene cyanol FF
15% Ficoll 4000
120 mM EDTA
6x gel loading buffer 2 0,25% Orange G
50% Glycerin
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2.1.2.2. Other solutions and medium 
LB-medium 1%(w/v) Trypton (AppliChem)
0,5%(w/v) Yeast extract 
         (AppliChem)
1%(w/v) NaCl
pH 7,0
Agar plates LB-Medium
1,5%(w/v) Bacto-Agar (Difco)
100 µg/ml Ampicillin
SOC-medium 2%(w/v) Trypton (AppliChem)
0,5%(w/v) Yeast extract
       (AppliChem)
10 mM NaCl
2,5 mM KCl
10 mM MgCl2
20 mM Glucose
pH 7,0
X-Gal (5-bromo-4-chloro-3-indolyl-β-D-galactoside) stock solution 
(40 mg/ml):
Dissolve 400 mg X-Gal in 10 ml dimethylformamide.
Protect from light by storing in a brown bottle at -20°C.
Add to agar plates to final concentration 20-40µg/ml.
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IPTG (isopropyl-β-D-thiogalactoside) stock solution (100 mM):
Dissolve 238 mg of IPTG in 10 ml deionized water.
Filter-sterilize and store in aliquots at -20°C.
Add to agar plates to final concentration 0,1 mM.
Ethidium bromide 10 mg/ml in distilled H20
DMEM complete DMEM
10 % (v/v) FCS (PAA Laboratories)
2 mM L-glutamine
100 U/ml Penicillin
100 µg/ml Streptomycin
RPMI 1640 complete RPMI 1640
10 % (v/v) FCS
2 mM L-glutamine
100 U/ml Penicillin
100 µg/ml Streptomycin
Acrylamide/bisacrylamide 38:2 (w/w)
38 g acrylamide
2 g bisacrylamide
H2O to 100 ml
Store ≤1 month at 4°C
0,5 M EDTA (pH 8,0) 186,1g Na2EDTA×2H2O
700 ml H2O
adjust pH to 8,0 with 
10 M NaOH (~50 ml)
add H2O to 1 liter
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Stop/loading dye in deionized formamide:
0.05% (w/v) bromphenol blue
0.05% (w/v) xylene cyanol
20 mM EDTA
4% denaturing acrylamide gel
75,6 g Urea
18 ml 38% acrylamide/
2%bisacrylamide mix
18 ml 10x TBE buffer
180 µl TEMED
500 µl 10% (w/v) APS
Transfer solution for downward alkali blotting
3 M NaCl
8 mM NaOH (pH 11,4)
Neutralizing solution (0,2 M sodium phosphate buffer, pH 6,7-6,8)
46,3 ml of 1 M Na2HPO4 
53,7 ml of 1 M NaH2PO4 
H2O to 500 ml
Stripping solution 1% SDS
0,1 x SSC
40 mM Tris-Cl, pH 7,5-7,8
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Denaturation solution for FISH 70% formamide
20x SSC
adjust pH to 7,0-8,0
Formamide wash solution 50% formamide
2x SSC
adjust pH to 7,0-8,0
2.1.2.3. Molecular weight markers
100 bp DNA Ladder (New England BioLabs) with 1517, 1200, 1000, 900, 800,
700, 600, 500/517, 400, 300, 200, 100 bp fragments.
1 kb DNA Ladder (Gibco BRL) with 12216, 11198, 10180, 9162, 8144, 7126,
6108, 5090, 4072, 3054, 2036, 1636, 1018, 517/506, 396, 344, 298, 220, 201, 154,
134, 75 bp fragments. 
λ DNA/Hind III (Gibco BRL) with 23130, 9416, 6557, 4361, 2322, 2027, 564 bp
fragments.
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2.1.3. Bacterial strains, cloning vectors and plasmids
2.1.3.1. Bacterial strains
XL1-Blue Stratagene 
F´ Tn10  proA+B+ lacIq ∆(lacZ)M15/recA1 endA1
gyrA96 (Nalr) thi hsdR17 (rK-mK+) supE44 relA1 lac
INVαF´ Invitrogen 
F´ endA1 recA1 hsdR17 (rk-, mk+) supE44 thi-1
gyrA96 relA1 φ80lacZ∆M15 ∆(lacZYA-argF)U16 λ-
TOP10F´ Invitrogen 
F´ {lacIq Tn10 (TetR)} mcrA ∆ (mrr-hsdRMS-
mcrBC)φ80lacZ∆M15 DlacX74 recA1 araD139 
∆(ara-leu)7697 galU galK rpsL (StrR) endA1 nupG
2.1.3.2. Cloning vectors
pCR2.1 Invitrogen 
Vector pCR2.1 pCR2.1 contains the lacZ-alpha
complementation fragment for blue-white color
screening, ampicillin and kanamycin resistance
genes for selection, and a versatile polylinker.
pcDNA3.1/Zeo Invitrogen 
pcDNA3.1 vector is designed for high-level,
constitutive expression in a variety of mammalian
cell lines. It contains Zeocin resistance gene for
antibiotic selection.
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2.1.3.3. RZPD clones
Clone ID Gene cloning vector
IMAGp998O245500Q2 STAT5a pCMV-SPORT6
IMAGp998E234965Q2 STAT5b pT7T3-Pac (mod)
IMAGp998F035797Q2 SRF pT7T3-Pac (mod)
2.1.4. Oligonucleotides and primers
All oligonucleotides were synthesized at MWG-Biotech. The lyophilized
primers were dissolved in distilled water at a stock concentration of 100
pmol/µl and stored at -20°C in aliquots.
Primer name Primer sequence Location
EGR-1 promoter1 CAA AGC CGG TCC TCT CTT CG EGR-1 gene
promoter
EGR-1 promoter2 AAC CAG CTC GGA CCG GAA TG EGR-1 gene
promoter
EGR-1 promoter3 CGG GCC ACT CCA AAT AAG GTG EGR-1 gene
promoter
EGR-1 promoter4 TGG TGG GCG AGT GAG GAA AG EGR-1 gene
promoter
EGR1_2527-2545 TTC TCA GTG TTC CCC GCG C EGR-1 mRNA
5’-UTR
EGR1_a GGA ACA GAG GAG TAC GTG GTG EGR-1 mRNA
CDS
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EGR1_CDS-2521f GCA CGC TTC TCA GTG TTC C EGR-1 mRNA
5’-UTR
EGR1_CDS-5038r TCT CCT CCT CCT GTC CTT TAA G EGR-1 mRNA
3’-UTR
EGR1_forward GGA GTC GCG AGA GAT CCA GC EGR-1 gene
promoter
EGR1_s TTC CAG GTT CCC ATG ATC C EGR-1 mRNA
CDS
EGR1c-2906f TTC AAC CCT CAG GCG GAC AC EGR-1 mRNA
CDS
EGR1c-3852r GCT CAC TAG GCC ACT GAC CAA G EGR-1 mRNA
CDS
EGR1-CDS-
2527forw
TTC TCA GTG TTC CCC GCG C EGR-1 mRNA
5’-UTR
EGR1-CDS-
2549forw
GCA TGT AAC CCG GCC AG EGR-1 mRNA
5’-UTR
EGR1-CDS-5213rev AAG AAC TTG GAC ATG GC EGR-1 mRNA
3’-UTR
EGR-1promoter
forw.
CGG TTC GCT CTC ACG GTC CC EGR-1 gene
promoter
EGR-1promoter
rev.
GCT GGA TCT CTC GCG ACT CC EGR-1 gene
promoter
hum.actin, sense CCA TGT ACG TTG CTA TCC AGG Human actin
mRNA CDS
hum.actin,
antisense
TGC CAA TGG TGA TGA CCT G Human actin
mRNA CDS
TAXREB107,
antisense
GGT CAG TCA CAA GTA ATA AGC TAXREB107
mRNA CDS
TAXREB107, sense CCA GAT ACT AAA GAG AAG AAA
C
TAXREB107
mRNA CDS
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rf180 TGG ACG TTG GCS Random primer
rf187 TGC TGC AGG ACS Random primer
rf24 GGA GAA GCT GCS Random primer
rf328 GCA GCA TCC GGW Random primer
rf417 ATG GCA ACG GCS Random primer
rf522 GGC ACA TTG CGS Random primer
rf567 CCA GAT GCC CGW Random primer
rf688 AAG CTG CTC GCS Random primer
rf942 ACG CCA TCG ACS Random primer
rf95 TCG ATG CCG CTS Random primer
T3 AAT TAA CCC TCA CTA AAG GG Standard primer
M13reverse CAG GAA ACA GCT ATG ACC Standard primer
T7 GTA ATA CGA CTC ACT ATA GGG C Standard primer
2.1.5. Eukariotic cell lines
Jurkat wild type (ATCC):
Human acute T cell leukemia cell line
HL 60 (ATCC):
Promyelocytic leukemia cell line
2.1.6. Enzymes
Enzymes used in this work were obtained from Roche Diagnostics GmbH,
Gibco BRL, MBI Fermentas Molecular Biology GmbH, New England BioLabs,
Pharmacia, Promega, Serva, Sigma-Aldrich Chemie GmbH and Stratagene
GmbH.
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2.1.7. Antibodies
Antibodies Clone Isotype Conjugate Producer
CD15 HI98 IgM, κ (Mouse) PE PharMingen
GmbH
CD34 8G12 IgG1 (Mouse) FITC Becton
Dickinson
GmbH
CD34 581 IgG1, κ (Mouse) PE Becton
Dickinson
GmbH
CD34 AC136 IgG2a (Mouse) FITC Miltenyi Biotec
CD55 IA10 IgG2a, κ (Mouse) Biotin,
FITC, PE
PharMingen
GmbH
HLA-ABC W6/32 IgG2a (Mouse) FITC Serotec
Isotype
Controls
DAK-GO1 IgG1 (Mouse) FITC, PE DAKO
2.1.8. Other materials
3MM filter paper Whatman
15 ml and 50 ml tubes Greiner
Nybond N+ Amersham Pharmacia Biotech
Petri dishes Nunc
Pipet tips Eppendorf
0,5; 1,5 and 2 ml tubes Eppendorf
0,2 ml thinwall PCR tubes Biozym
Cell culture flasks Nunc
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2.1.9. Kits
QIAprep Spin Miniprep Kit QIAGEN
NucleoSpin Plasmid isolation Kit Macherey-Nagel GmbH
GFX PCR DNA band and Gel
Purification Kit Amersham Pharmacia Biotech
Original TA Cloning Kit Invitrogen BV
TOPO TA Cloning Kit Invitrogen BV
TRizolTM Total RNA Isolation Reagent GibcoBRL
RNeasy Mini Kit QIAGEN
RadPrime Labeling System GibcoBRL
QIAamp DNA Blood Mini Kit QIAGEN
Atlas pure Total RNA Labeling System Clontech
ExpressHyb buffer Clontech
Atlas Hematology cDNA array Clontech
2.1.10. Laboratory equipment
1214 Rackbeta liquid scintillation counter (LKB)
2219 Multitemp II thermostatic circulator (LKB)
Biofuge 13 (Heraeus)
Cell culture incubators (Heraeus)
Centrifuge 5415 (Eppendorf)
Centrifuge, model J2-21, rotor JA14 and JA17 (Beckmann)
Centrifuge, model J-6B (Beckmann)
Centrifuge, model J6-MC (Beckmann)
Diavert fluorescence microscope (Leitz)
Diavert light microscope (Leitz)
Digital-pH-meter (Knick)
EasijectTM plus electroporation (Eurogentec)
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Eclipse TE 300 fluorescence microscope (Nikon)
FACScalibur with CellQuest software (Becton Dickinson)
G24 environmental incubator shaker (New Brunswick Scientific Co. Inc.)
Gel Doc 1000 (Bio-Rad Laboratories GmbH) 
GFL water bath (H. Juergens & Co.)
Horizontal electrophoresis (Bio-Rad Laboratories GmbH and Pharmacia)
Laminar air flow class 100 (Gelaire)
Magnetic cell separator, MACS (Miltenyi Biotec)
Megafuge 2.0 R (Heraeus)
Minifuge T (Heraeus)
PhosphorImager FujiFilm BAS1500 (Fuji)
SpeedVac plus SC 110A (Savant)
Sterile GARD hood (Baker Company, Inc.)
Thermocycler varius V45 (Landgraf)
T3 Thermocycler   (Biometra)
Thermomagnetic stirrer, MR 2002 (Heidolph Instruments)
Thermomixer 5436 (Eppendorf)
Thermostat 5320 (Eppendorf)
UV-VIS Spectrophotometer, UV-1202  (Shimadzu Deutschland GmbH)
Vortex Genie 2TM (Bender and Hobein AG)
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2.2. Methods
2.2.1. DNA-Modification
For modifying DNA, reactions with restriction enzymes, T4 DNA polymerase,
alkaline phosphatase and T4 DNA ligase, were performed in accordance with
the suppliers’ instructions.
2.2.2. Plasmid isolation
For isolation of plasmids we used QIAprep Spin Miniprep Kit or NucleoSpin
Plasmid Kit.
The two methods are identical and designed for rapid and small-scale (20-40
µg) preparation of highly pure plasmid DNA (< 10 kb) from 1-8 ml of
overnight E. coli culture. The mini-preparation of plasmid was carried out
following the manufacturer’s instructions. Briefly, the bacteria pellet was
resuspended in RNase A-containing buffer 1 and E. coli host cells were lysed
by SDS/alkali containing buffer (buffer 2). Buffer 3 was added to neutralize
the resulting lysate and create appropriate conditions for binding of plasmid
DNA to the silica membrane in QIAprep spin or NucleoSpin plasmid column.
After following centrifugation step, the clear supernatant without SDS
precipitate and cell debris was loaded onto QIAprep spin or NucleoSpin
plasmid column. If host strains with high nuclease levels were used, a
washing step with buffer PB (QIAprep Spin Miniprep Kit) or AW
(NucleoSpin Plasmid Kit) was performed. Washing with ethanol-containing
buffer removed salts, metabolites and soluble macromolecular cellular
components. Pure plasmid DNA was finally eluted with 50 µl distilled water
and stored at -20°C.
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2.2.3. RNA isolation
Total cellular RNA was extracted using TRIzol reagent in accordance with the
recommendations of the manufacturer (GibcoBRL). Quality of the every RNA
preparation was monitored by the A260 /A280 ratio and agarose-formaldehyde
gel.
2.2.4. Genomic DNA isolation
Genomic DNA was isolated from whole blood by QIAamp DNA Blood Kit in
accordance with the recommendations of the manufacturer (QIAGEN).
2.2.5. Polymerase chain reaction (PCR)
A standard PCR reaction was held as follows: 30 µl end reaction volume
(filled up with dH2O) with 100-300 ng genomic DNA or 20 ng plasmid DNA,
20-100 pmol of each primer, 200 µM dNTPs, 0,3 U Taq polymerase Gold and
1x buffer (including 1.5 mM MgCl2) of polymerase supplier.
DNA was initially denatured at 95°C and incubated for 10 min in order to
activate Taq polimerase Gold. PCR was carried out with 25 - 35 cycles for each
45 sec at 95°C; 45 sec at annealing temperature and 45 sec - 2 min extension at
72°C, depending on the length of DNA molecule to amplify. Final extension
step was performed at 72°C for 5 – 15 min.
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2.2.6. RT-PCR
2.2.6.1. First strand cDNA synthesis
In a sterile RNase-free microcentrifuge tube, 0.5 µg (1 µl) oligo(dT)15 primer
(Promega) was added to 1-5 µg of total RNA (treated or not with DNase I,
RNase-free) in a total volume of 10 µl nuclease-free water. The tube was
heated to 70°C for 10 min and immediately cooled on ice to prevent RNA
renaturation followed by briefly centrifugation to collect the fluid at the
bottom of the tube. The following components were added to the
primer/template mixture in the following order:
5 X M-MLV reaction buffer 5 µl
10 mM dNTP´s (Promega) 1.25 µl
25 U rRNasin ribonuclease inhibitor
(Promega)
0.6 µl
nuclease-free water 7.15 µl
200 U M-MLV reverse transcriptase (Promega) 1 µl
The reaction mixture was incubated for 60 min at 37°C. M-MLV enzyme was
inactivated by incubation at 95°C for 3 min and the tube was cooled on ice.
First strand cDNA was stored at -80°C or the reverse transcriptase-
polymerase chain reaction (RT-PCR) was immediately performed.
2.2.6.2. Reverse transcriptase-polymerase chain reaction
PCR reaction was held as follows: 5 µl of first strand cDNA from RT-step, 50
pmol of each primer, 200 µM dNTPs, 0,3 U Taq polymerase Gold and 1x
buffer (including 1.5 mM MgCl2) of polymerase supplier in 30 µl end reaction
volume (filled up with dH2O).
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DNA was initially denatured at 95°C and incubated for 10min in order to
activate Taq polimerase Gold. PCR was carried out with 25 - 35 cycles for each
45 sec at 95°C; 45 sec at annealing temperature and 45 sec - 2 min extension at
72°C, depending on the length of DNA molecule to amplify. Final extension
step was performed at 72°C for 5 – 15 min.
2.2.7. Purification of PCR products and DNA fragments from gel bands
PCR products and DNA fragments from gel bands were purified with GFX
MicroSpin columns following the instructions of the supplier (GibcoBRL).
Briefly, 300 mg (the maximum weight that can processed with this procedure)
of gel slice was dissolved in 300 µl capture buffer, mixed vigorously by
vortexing and incubated at 60°C (5-15 min) until the agarose was completely
dissolved. The sample was passed through the GFX column to capture the
DNA onto the glass fiber matrix. Matrix-bound DNA was washed with an
ethanol-containing buffer to remove any contamination. DNA was eluted
from the column in a volume of 50 µl dH2O.
2.2.8. Determination of nucleic acids concentration 
To determine the concentration and purity of the isolated RNA and plasmid
DNA, the absorption of diluted solution was measured by UV
spectrophotometer at 260 nm (and at 280 nm in case of RNA). The dilution
was performed to make the absorption between 0.1 and 1.0 OD.
Concentrations of nucleic acids were calculated as follows: 
RNA concentration (µg/µl) = A260 × dilution factor × 40 /1000
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DNA concentration (µg/µl) = A260 × dilution factor × 50 /1000 
Purity of RNA was determined by A260/ A280 ratio.
2.2.9. Precipitation of nucleic acids
To 1 volume of DNA or RNA solution 0,1 volume of 3 M NaAc (pH 5,2) and
2.5 volumes of Ethanol (or 0,7 volumes of Isopropanol) were added and
mixed. After storing for at least 30 min at –20°C the mixture was centrifuged
for 15 min with maximum speed. After discarding the supernatant the pellet
was washed twice with 70% Ethanol and centrifuged for 5 min with
maximum speed.
The supernatant was discarded and nucleic acid pellet was air dried for 10
min, resuspended in dH2O and stored at -20°C.
2.2.10. Electrophoretic separation of nucleic acids
2.2.10.1. Electrophoresis of DNA in agarose gel
0.7%-1.2% (w/v) agarose gels containing 0,1 µg/ml ethidium bromide were
used for analysis of plasmid DNA and PCR products. 1x TAE-buffer was
used as gel and electrophoresis buffer. DNA samples were loaded into the
gels in 1x DNA loading buffer 1 or 2 and run at 10 V/cm of the gel. Generally
samples were run in parallel with a DNA molecular weight marker. The
samples were visualized by Gel Doc 1000 (Bio-Rad) system and analyzed by
molecular analysis software (Bio-Rad).
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2.2.10.2. Electrophoresis of DNA in acrylamide gel
Electrophoresis in 4% denaturing acrylamide gel was used to resolve
fragments, obtained from PCR-based RNA fingerprinting. 
DNA sample/ stop-loading dye mixture was loaded into the gel. Gel was run
in TBE buffer at a constant power 75 W and temperature kept below 55°C
until xylene-cyanol reaches the bottom of the gel. The gel was transferred
onto 3MM filter paper, vacuum dried and exposed overnight to Kodak MS
film.
2.2.10.3. Electrophoresis of RNA in formaldehyde/agarose gel
RNA samples were mixed with 3-5 volume of RNA loading buffer (Sigma),
denatured for 15 min at 65°C and briefly centrifuged before loading. The
samples were separated in formaldehyde-agarose gels (1,2% (w/v) agarose,
1x MOPS buffer, 2,2 M formaldehyde). Gels were run at 5 V/cm in 1x MOPS
buffer at 4°C.
2.2.11. Downward alkaline blotting of RNA
Downward alkaline capillary transfer for RNA blotting was performed as
described in (Chomczynski 1992). Briefly, denaturing gel containing RNA
samples was placed onto the bottom base formed by 2-3-cm-high stack of
paper towels, several blotting papers and nylon membrane (Nybond N+,
Amersham) well soaked in distilled water. Than the gel was covered with
three shits of blotting paper and two sheets of blotting paper forming a
connection (bridge) between the gel stack and tray containing the transfer
solution. After 1,5-2 hour of transfer, the membrane was washed in
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neutralizing solution, put between 2 Whatman sheets, air-dried overnight and
baked in an oven for 20 minutes at 80°C.
2.2.12. Northern blot analysis
For Northern blot analysis, samples (2-10 µg) of total RNA were resolved by
electrophoresis on 1,2% agarose, 2,2 M formaldehyde gels and blotted onto
nylon membranes (Hybond N+, Amersham) using downward alkaline
capillary transfer (Chomczynski 1992). Filters were hybridized in ExpressHyb
solution (Clontech) following the manufacturer’s instructions. Filters were
visualized by autoradiography, than exposed to the storage phosphor screens
and quantitated by PhosphorImager (FujiFilm BAS1500). Obtained images
were analyzed using AIDA software. The intensity of signals was normalized
to beta-actin as a housekeeping gene.
2.2.13. Cloning
Cloning of gel purified DNA fragments and PCR products into pCR2.1
vector was performed with T4 DNA ligase. The Original TA Cloning Kit
contains linearized pCR2.1 vector and provides a quick, one-step cloning
strategy for the direct insertion of a PCR product into plasmid vector. The
linearized vector has single 3`deoxythymidine (T) residues. The ligation
reaction was performed with 1:1 or 1:3 (vector:insert) ratio in a 10 µl volume
as follows:
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Gel purified PCR product or 
DNA fragment
X µl
10 × ligation buffer 1 µl
Vector 2 µl
Sterile water to a total volume of 9 µl
T4 DNA ligase (4 units) 1 µl
The ligation reactions were incubated overnight at 14°C. Than they were
stored at -20°C until ready for transformation.
2.2.14. Transformation of chemocompetent E. coli
100 µl of competent E.coli cells were added to an ice-cold DNA suspension
(50-100 ng DNA dissolved in 10 µl dH2O).
The mixture was incubated for 30 min on ice, then heat shocked for 90 sec at
42°C and afterwards cooled down on ice for 2 min. After adding 1 ml of SOC
media, suspension was incubated being shacked for 45 min at 37°C. Aliquots
of 100 - 500 µl were plated on appropriate selection media and incubated
overnight at 37°C.
2.2.15. DNA sequencing
DNA sequencing was performed by MWG-Biotech sequencing service using
the M13 reverse primer and T7 primer. 
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2.2.16. Eukariotic cell culture
2.2.16.1. General cell culture
Generally, adherent and suspension cells were grown at 37°C and 5% CO2 in
incubator. The saturated cultures were splited every 3 days. Cell density 105 –
106 cells/ml was maintained. To split and passage adherent cells, the cells
were gently rinsed with PBS and trypsinized until the cells were easily
detached. Trypsinization was quenched with medium prior to subculturing in
fresh medium. 
2.2.16.2. Cell counting
Suspension and trypsinized viable cell counts were performed using a
Neubauer chamber (Hawksley & Sons Limited) with at least 200 cells being
counted per sample. Cell viability was determined using trypan blue
exclusion (Sigma-Aldrich Chemie GmbH). 
2.2.16.3. Cells freezing down
To freeze suspension and trypsinized cells, the cells were centrifuged at 500xg
for 5 min and the media was discarded. One ml of cold freezing solution (90%
heat-inactivated fetal calf serum, 10% DMSO) per 106 cells was added
immediately and the cells were transferred to a cold 2 ml cryogenic vial. After
that the vial was placed overnight at -70°C and transferred to liquid nitrogen
on the following day.
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2.2.16.4. Cells thawing
To thaw the frozen cells, one vial was removed from liquid nitrogen and
thawed rapidly at 37°C. 1 ml of medium was added immediately to the vial
and the cells were gently transferred to a 15 ml sterile conical screw cap tube.
Then 10 ml of medium was gently added and the suspension was mixed by
inverting. After centrifugation at 500xg for 5 min the supernatant was
removed, cells were resuspended in 10 ml of medium (105-106 cells/ml) and
cultured in 25 cm2 tissue culture flasks with filter cap at 37°C and 5% CO2.
2.2.17. Generation of T-cell lines from patients with PNH
T-cell lines were generated as described in detail previously (Ostendorf et al.
1995). Briefly, cells were plated, at 1000 cells/well, onto a feeder layer of
irradiated (5000 cGy) allogeneic PBL and EBV-transformed B-lymphoblastoid
cells (Laz509). Colonies were expanded at 1000 cells/well in culture medium
containing 10% lymphocyte-conditioned medium. The polyclonal T-cell lines,
either normal or deficient for GPI-anchored proteins, were generated from
CD48+ and CD48- sorted PBL of patients with PNH. After the first round of
expansion, contaminating NK cells were depleted by using CD16 mAb B73.1
and the CD56mAb anti-Leu-19, followed by magnetic separation by using
sheep anti-mouse antibody-loaded magnetic beads (Dynabeads; Dynal,
Hamburg, Germany). A similar procedure with the use of CD48 antibodies
MEM-102 was performed in order to remove contaminating CD48+ from
CD48- T-cell lines. Re-analysis revealed a purity of CD3+ and CD48+ or
CD48- cells of >95% in each experiment.
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2.2.18. Isolation of mononuclear cells and granulocytes
Heparinized blood samples were obtained either from normal adult donors or
from patients with PNH or other hematological diseases, and then
centrifuged for 8 minutes at 800 rpm to collect plasma. After taking off
plasma, blood cell pellet was mixed with an equal volume of RPMI 1640
medium and fractionated by centrifugation over Ficoll-Hypaque (Biochrom
KG, Berlin, Germany). Mononuclear cells were harvested from the interphase
of Ficoll density gradient. Granulocytes from the Ficoll gradient pellet were
separated from erythrocytes by sedimentation in Gelafundin 4% (B.Braun
Melsungen AG) followed by the hypotonic lysis and washing. The isolated
granulocyte fraction was subjected to flow cytometry analysis to exclude
possible cellular contaminations, i.e. with monocytes.
2.2.19. PCR-based RNA fingerprinting
Modified arbitrarily primed PCR fingerprinting of RNA (Welsh et al. 1992)
was conducted as follows. A reverse transcription reaction was carried out
using oligo(dT)15 primer on DNase I treated total RNA. Each of radioactively
labeled PCR reactions was performed from 5 µl of RT-reaction in a 50-µl final
volume with one of 10 computer designed arbitrary 12-mer primers (final
concentration 4 µM) (Consalez et al. 1999). In order to control the RNA
amplification procedure and maximize efficiency of fingerprinting, all of RT-
and PCR-reactions were carried out in duplicate. Amplified products were
separated on 4% denaturing acrylamide gel and visualized by
autoradiography. Differentially displayed bands were cut out of gel,
electroeluted in TAE buffer and precipitated. The bands were reamplified
using the same 12-mer primers, cloned into pCR2.1 vector (Invitrogen),
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sequenced and subjected to further analysis. In order to preliminary screen
obtained clones plasmids were blotted onto nylon membranes and hybridized
with random primer labeled PCR mixture from the previous step.
2.2.20. cDNA array
Atlas membranes with 406 known genes (Clontech) were used. Radioactive
cDNA probes were synthesized with Atlas pure Total RNA Labeling System
(Clontech) on the base of RNA from 2 independent sets of GPI-positive and
GPI-negative clones (CD48+ and CD48- T-lymphocyte cell lines from the
same PNH patient) and hybridization was performed according to the
manufacturer’s recommendations. The signals were controlled by the signals
of housekeeping genes and visually analyzed. Only those genes with strong
signal differences were preliminarily considered as modulated.
2.2.21. Bioinformatics analysis
All obtained gene fragments were sequenced and searched against GenBank,
dbEST and SwissProt databases through the BLAST server. The sequences
were considered to be a part of known genes if they have 98% or more
homology over at least a 200-bp DNA sequence in BLAST search. 
For the gene analysis we used PubMed, GenBank, Entres, Locuslink, OMIM,
UniGene databases and search engines.
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2.2.22. Flow cytometric analysis (FACS)
Cells of interest (~105) were washed twice with ice-cold PBS and resuspended
in 200 µl of staining buffer (PBS/0.2 % BSA) in 96-well plates. Fluorescein
isothiocyanate (FITC)- or phycoerythrin (PE)-marked mAbs in appropriate
concentrations were added to cell suspension following the instructions of
supplier. After 30 min of incubation at 4°C and two washes with PBS cells
were ready for incubation with secondary antibody or for phenotypic analysis
on flow cytometer (FACScalibur with CellQuest software, Becton Dickinson).
Nonspecific binding was blocked by FcR blocking reagent (Human IgG,
Miltenyi Biotec). Appropriate conjugate isotype-matched Abs served as
controls. Ten thousand cells from each sample were analyzed on flow
cytometer. Data presentation was performed using WinMDI version 2.8
software. 
2.2.23. In vitro stimulation of granulocytes
Granulocytes were suspended to 2×106 cells/ml in RPMI 1640 medium and
incubated with 0,1 µg/ml G-CSF and with 0,1 µg/ml GM-CSF (TeBu) for 30
minutes, 1 hour, 1,5 hours and 2 hours at 37°C.
Granulocytes were obtained from normal donor and incubated (1×107
cells/ml) in plasma of normal donors and PNH patients for 0,5; 1,5; 2 and 4
hours at 37°C.
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2.2.24. Fluorescence in situ hybridization analysis (FISH)
FISH was performed on granulocytes according to the instructions of the
supplier. Briefly, up to 2×107 freshly isolated granulocytes were incubated in
ice cold 0,075 M KCl for 10 min at room temperature. After 10 min
centrifugation at 1200 rpm cell pellet was carefully resuspended in 10 ml of
acetic acid/methanol (1:3) mix and incubated at room temperature for 25 min
for fixation. Cells were stored at -20°C until ready for FISH.
100 µl of cells (density of 2×107 cells/ml) were pipetted in a drop onto cold
glass slide and dried at room temperature. After denaturation at 73±1°C
(denaturation solution) for 5 min glass slides were subsequently dehydrated
in 70%, 85% and 100% ethanol for 1 min each and dried. Just before
hybridization 10 µl of the LSI 5q EGR1 SO/ D5S23 SG probe was denatured at
73°C for 5 min and stored at 45-50°C.  Glass slides were prewarmed at 45-
50°C for 2 min and 10 µl of the probe was pipetted on the target area of each
slide. Hybridization was performed at 37°C overnight, and subsequent
washes were done at 46±1°C as follows: 3 times in 50% formamide/2×SSC for
10 min each, 2×SSC for 10 min, 2×SSC/0,1% NP-40 for 5 min. To visualize
hybridization slides dried in darkness and 10 µl of counterstain (DAPI
150ng/ml) to the target area of the slide and coverslip were applied.
After hybridization the mean number of signals scored for each sample after
counting 200 nuclei.
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3. Results
In this work several genes differentially expressed in GPI-positive and GPI-
negative cells of PNH patients were identified. In further studies expression
of two genes was investigated, confirmed and characterized in PNH.
3.1. Identification of genes differentially expressed in GPI-positive and GPI-
negative cells in PNH
In order to reveal differentially regulated genes responsible for the growth
advantage and clonal expansion of the GPI-deficient clone in PNH, we have
employed combination of two different approaches: the RNA fingerprinting
technique and cDNA array hybridization. cDNA array hybridization
technique allowed us to compare expression of hundreds of previously
characterized genes at the same time. PCR-based RNA fingerprinting is
powerful method to analyze expression not only known genes but also novel
ones. 
3.1.1. Generation of GPI-positive and GPI-negative PNH clones
As a model of GPI-positive and GPI-negative PNH clones we used the CD48+
and CD48- T-lymphocyte cell lines from the same PNH patient (A.P.)
generated as described in Methods. Important that these cell lines have been
obtained without any immortalization step (virus-transformation, etc.). The
purity of GPI-negative and GPI-positive clones was monitored by flow
cytometric analysis for every experiment (Figure 4). Cells have been used for
further analysis only when purity more than 95% was detected.
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Figure 4: CD48+ and CD48- T-lymphocyte cell lines from the same PNH patient used
as a model of GPI-positive and GPI-negative PNH clones. Results of flow cytometric
analysis for the surface expression of CD48 are shown. CD48 fluorescence is
presented as regular line, dashed line indicates isotope control.
Both employed techniques − the RNA fingerprinting technique and cDNA
array hybridization analysis − require RNA as a starting material. Therefore,
we isolated total cellular RNA from of GPI-positive and GPI-negative PNH
cell lines. Then the total RNA was treated with DNase I to remove any tracks
of genomic DNA to enhance result of gene expression profiling. The quality
of RNA was monitored by agarose/formaldehyde denaturing electrophoresis
and by ratio of optic density A260 to A280. We used RNA in further
experiments only when 28S rRNA band was approximately two fold brighter
than 18S rRNA band and A260/A280 ratio was higher than 1,8.
3.1.2. Atlas cDNA expression array hybridization
Analysis of gene expression can be accomplished using PT-PCR, RNase
protection assays, or Northern blot analysis, but these methods focus on only
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a few genes at a time. A more promising approach for analyzing multiple
genes simultaneously is the hybridization of entire cDNA populations to
nucleic acid arrays.
In this study we used human Atlas Hematology cDNA Expression Array
from Clontech. It includes 406 known genes shown to play a role in human
hematopoiesis and belonged to different functional classes.
Radioactive cDNA probes were synthesized with Atlas pure Total RNA
Labeling System (Clontech) on the base of RNA from 2 independent sets of
GPI-positive and GPI-negative clones (CD48+ and CD48- T-lymphocyte cell
lines from the same PNH patient). Hybridizations with separate Atlas
Hematology cDNA arrays were performed simultaneous for both analyzing
probes according to the manufacturer’s recommendations. The images were
obtained by autoradiography (Figure 5). The differential signals were
controlled by the signals of housekeeping genes and visually analyzed. Only
those genes with strong signal differences were preliminarily considered as
modulated.
3.1.3. PCR-based differential screening – RNA fingerprinting
The PCR-based differential screening − RNA fingerprinting can be
successfully applied not only to identify differentially expressed genes, but
also to isolate and characterize novel ones. It is based on the reverse
transcription of mRNAs and PCR using arbitrary primers.
In this study we used modified arbitrarily primed PCR fingerprinting of RNA
with 10 computer designed arbitrary 12-mer primers (described in detail in
Materials and Methods). All of RT- and PCR-reactions were carried out in
duplicate in order to control the RNA amplification procedure and maximize
efficiency of fingerprinting. Amplified products were separated on
denaturing acrylamide gel and visualized by autoradiography (Figure 6).
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Figure 5: Gene expression profiling using Hematology Atlas cDNA Expression
Array. 32P-labelled cDNA probes were prepared from 25 µg of total RNA isolated
from CD48+ and CD48- T-lymphocyte cell lines from the same PNH patient (panel A
and B corresponding). The probes were simultaneously hybridized to separate Atlas
Hematology Array membranes. Results were analyzed by autoradiography. 
A
B
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Figure 6: PCR-based differential screening - RNA-fingerprinting. Total RNA was
isolated from GPI-positive and GPI-negative PNH lines, reverse transcribed and
subjected to amplification of coding region fragments with computer-designed
arbitrary primers. Obtained PCR-products were resolved by polyacrylamide gel.
Part of the gel is presented.
Differentially displayed bands were cut out of the gel and electroeluted. The
PCR fragments were reamplified using the same 12-mer primers and screened
for probe specificity as described in Methods. After screening all positive PCR
products were cloned, sequenced and subjected to further analysis.
3.1.4. Genes found to be differentially expressed in GPI-deficient PNH cells.
Finally, a number of candidate genes and cDNA clones were identified as
being differentially expressed in GPI-deficient cells. cDNA array
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hybridization analysis revealed 15 out of 406 genes, involved in human
hematopoiesis, exhibiting a significant difference of expression levels (Table
1). Among these 15 genes, 7 out of them were up-regulated in GPI-deficient
cells, and 8 displayed down-regulated signals.
PCR-based RNA fingerprinting gave rise to a total of 11 sequences with
confirmed differential regulation. Sequence analysis of these clones led to
identification of 4 known genes, 4 novel sequence fragments, and 3 were
matched repetitive elements (Table 1). Expression of identified genes was
further tested by RT-PCR and Northern blot analysis.
Name of
protein/gene
GenBank
accession #
Difference in
expression
Name of
protein/gene
GenBank
accession #
Difference
in
expression
CALLA; CD10 antigen X07166 − MLR3; BL-AC/P26; AIM L07555 −  −  −
TAXREB107; C140 X69391 + + + GZMK; fragmentin 3 U35237 + + +
ID2 M97796 − chromosome 9 NT_008387.2 +
DEK protein X64229 − Chromosome 14 AL117694 −
TOP1 J03250 +
Chromosome 9, Alu
repetitive element
NT_008528.2 +
SMMHC; MYH11 X69292 + + + P2X XM_008509 +
CREB1 M34356 − CDNA DKFZp434D2328 AL133087 + + +
BSG; EMMPRIN L20471 −  −  − Chromosome 6 NT_023346.2 −
LYT1 X04391 −  −  − L1 repetitive element,
chromosome 6, 7, 16
AC090497 +
MLLT6; AF17 U07932 + + + EGR1 NM_001964.1 + + +
STAT1 M97935 + HuMCM5 NM_006739.1 + + +
ITGA4; CD49D
L12002; X16983 −  −  − Chromosome 10, Alu
repetitive element
NT_008921.2
−
CD19; B4 M21097 + + + Chromosome 9 NT_008387.2 +
Table 1: Genes, found to be differentially expressed in GPI-deficient and normal cells
of PNH-patients. Two different approaches, the RNA fingerprinting technique and
cDNA array hybridization, revealed 26 genes differentially expressed in PNH. Plus
indicates strong (+ + +) to week (+) upregulation of the gene in GPI-deficient cells in
comparison to normal cells level, minus indicates strong (− − −) to week (-)
downregulation of the gene in GPI-deficient cells in comparison to normal cells level.
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All genes found to be differentially expressed in GPI-negative and GPI-
positive cells of PNH patients were subjected to bioinformatic analysis
(PubMed, GenBank, Entrez, Locuslink, OMIM, UniGene databases and search
engines). Data about structure, expression, cellular localization, function and
biological role of these genes have been considered in this analysis.
Finally, we have selected two candidate genes − Early Growth Response-1
Factor (EGR-1) and TAX-responsive enhancer element binding protein 107
(TAXREB107) − for the further work because of their more pronounced
differential expression and their role in regulation of hematopoiesis described
in the literature so far.
3.2. EGR-1 and TAXREB107: expression studies in patients
In experiments of identification of genes differentially expressed in GPI-
positive and GPI-negative PNH cell lines we found EGR-1 and TAXREB107 to
exhibit strong difference in expression level. Therefore, the objective of our
further studies was to find relation between the observed overexpression and
clonal expansion in PNH and investigate it in other hematological diseases. 
3.2.1. Patients used for analysis
Ten patients with PNH followed up at Hannover Medical School were
included in the study. The patients were aged between 35 and 60 years. All of
them have been tested by flow cytometry for the expression of GPI-linked
surface antigens. Five patients (S.N., A.P., T.C., A.S., W.E.) have more than
95% GPI-deficient granulocytes, two (K.G., J.S.) – 80-95%, and three (D.R.,
J.O., J.A.) – 50-80%. Four of them (A.P., T.C., A.S., E.W.) have been treated for
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aplastic anemia (AA) before the diagnosis of PNH had been made.
Cytological analysis of granulocytes revealed no changes in nuclear or
cytoplasmic maturation. All patients were in good clinical condition without
signs of infection, were not treated with G-CSF or GM-CSF. None of the
patients had been transfused for at least 3 month prior to the time of study.
In addition, peripheral blood samples from two patients with autoimmune
hemolytic anemia (AIHA), 2 with polycythemia vera, 1 with myelodysplastic
syndrome after severe aplastic anemia (MDS after SAA), one with MDS
transformed into AML after chemotherapy presenting with continuous
dysplastic signs on cytologic analysis of bone marrow, eleven patients with
other diseases such as thalassemia, CML, CMML, AML, ITP and ALL have
been analyzed (Table 2). Healthy volunteers served as controls. One of
healthy individuals was analyzed while having leucocytosis due to
sinubronchial infection (WBC 15G/L).
3.2.2. Construction of EGR-1-specific and β-actin-specific templates for
generation of radioactive probe for Northern blot analysis
For the Northern blot hybridization analysis we constructed gene specific
probes (described in detail in Methods). Briefly, 769 bp fragment of EGR-1 
cDNA was amplified by RT-PCR and cloned into pCR2.1 vector and
sequenced (Figure 7). The fragment was cut out of plasmid by EcoR I and
digested by Ava II in order to remove zinc finger coding region. Obtained 177
bp cDNA fragment (position 1008-1185 in GenBank sequence, accession #
NM_001964) is specific for EGR-1 gene and served as template in generation
of radioactive probe.
362 bp fragment of β-actin gene (position 467-829 in GenBank sequence,
accession # BC016045) was also amplified by RT-PCR reaction, cloned into
pCR2.1 vector, sequenced and excised by EcoR I enzyme. Radioactive probe
for Northern blot analysis was generated using obtained fragment.
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blood counts
Patient Diagnosis Sex Current therapy
GPI-
deficiency
(%) L (G/L) Hb (g/dL) T (G/L)
A.P. PNH/SAA f steroids > 95 6,2 7,6 49
S.N. hemol. PNH m none > 95 4,5 8,2 166
K.G. hemol. PNH m none 80-95 5,7 13,3 217
D.R. hemol. PNH f none 50-80 8,2 12,4 164
A.S. PNH/SAA m Cyclosporin∗ > 95 3,9 7,3 253
J.O. hemol. PNH m Cyclosporin∗ 50-80 3,6 11,1 70
T.C. PNH/SAA m Cyclosporin∗ > 95 3,3 7,4 42
J.S. PNH f none 80-95 3,7 10,7 129
W.E. PNH/SAA f none > 95 5,4 8,9 225
J.A. PNH f none 60-80 3,6 13,1 93
D.W. AIHA m MMF and steroids - 5,7 9,9 77
P.W. AIHA f steroids - 18,3 13,5 677
C.W. P.vera f Hydroxyurea - 2,6 12,9 432
G.H. P.vera m venous puncture - 7,0 9,6 238
K.M. SAA-MDS m SCF and G-CSF - 3,8 8,2 7
H.W. MDS-AML f
intermittent
chemotherapy - 3,4 10,5 66
D.W. ALL m G-CSF - 23,5 9,6 57
A.K. MPS f none - 10,1 13,1 1009
J.F. MPS m none - 8,3 15,3 870
H.H. MPS m transfusions - 9,6 14,9 228
W.D. CMML m Hydroxyurea - 8,2 10,9 56
M.B. OMF m Hydroxyurea - 3,6 9,7 232
L.G. ITP f Azathioprin and steroids - 3,8 9,8 33
T.K. CML f Hydroxyurea - 7,8 11,5 230
G.K. CLL m Chloramucil - 33,8 10,8 99
V.D. Talassemia f
transfusions,
splenectomy - 17,6 8,9 983
I.D. AML m none - 5,7 9,9 115
Table 2: Characteristics of patients studied. ∗ These patients were treated with Cyclosporin not at the
time of analysis.
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Figure 7: Construction of EGR-1-specific and β-actin-specific templates. Gene
fragments were amplified by RT-PCR, cloned into pCR 2.1 vector and sequenced.
For the preparation of radioactive probe inserts were cut out by EcoR I.
3.2.3. Expression of EGR-1 in PNH granulocytes
In order to study gene regulation in native PNH cells, we chose granulocytes
because in most patients with primary hemolytic PNH the vast majority of
granulocytes are GPI-deficient (>95%). In addition, granulocytes as myeloid
cells are optimally representing the relation of GPI-deficient and normal
progenitor cells in bone marrow of PNH-patient due to their short lifetime
(Prince et al. 1995). Therefore, we confirmed differential expression of EGR-1
by Northern blot analysis using GPI-deficient granulocytes of PNH patients
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in comparison to normal donors. Significantly upregulated EGR-1 gene
expression (5 times more than level for normal donors) has been observed for
all analyzed PNH patients (Figure 8).
Figure 8: Expression of EGR-1 in granulocytes.∗ A: Representative Northern blot of
total cellular RNA from GPI-deficient granulocytes of PNH patients in comparison
to granulocytes of normal donors, probed with EGR-1 (upper panel) and actin (lower
panel). B: Histogram showing densitometric analysis of representative Northern blot.
For all analyzed PNH patients significant overexpression of EGR-1 has been
observed.
                                                
∗ All bar diagrams are presenting mRNA levels quantified by PhosphorImager and normalized
to β-actin.
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3.2.4. Expression in granulocytes of patients with other hematological
diseases
Expression of EGR-1 in granulocytes obtained from patients with other
hematological diseases like MDS, SAA, AIHA was analyzed. Northern blot
analysis revealed an overexpression of this gene only in some cases of
myeloproliferative and myelodysplastic disorders. For normal donors and
patients with hemolytic anemia and a positive Coombs test, the expression of
EGR-1 was not significantly altered (Figure 9).
Figure 9: Expression of EGR-1 in granulocytes of patients with other hematological
diseases.∗ Analysis of expression in granulocytes obtained from patients with other
hematological diseases revealed an overexpression of this gene also in some cases of
myeloproliferative and myelodysplastic disorders.
                                                
∗ All bar diagrams are presenting mRNA levels quantified by PhosphorImager and normalized
to β-actin.















































EG
R
-1
 m
R
N
A
 le
ve
l*
A.P.    S.N.          A.K.    J.F.    H.H.           K.M.  H.W.           C.W.           D.W.            J.S.
     PNH                          MPS            SAA-MDS MDS-AML   P.vera       AIHA        normal
EG
R
-1
 m
R
N
A
 le
ve
l*
Results
54
In addition, EGR-1 expression was tested in patients with thalassemia, CML,
CMML, AML, ITP and ALL. In these patients no changes in EGR-1 expression
level have been observed (Figure 10).
Figure 10: Expression of EGR-1 in granulocytes of hematological patients∗. No
overexpression of EGR-1 detected in cases of AIHA, ITP, OMB, CML, CLL, CMML.
3.2.5. Construction of TAXREB107-specific template for generation of
radioactive probe for Northern blot analysis
For the Northern blot hybridization analysis we constructed TAXREB107
gene specific probe (described in detail in Methods). Briefly, 507 bp fragment
of TAXREB107 cDNA was amplified by RT-PCR and cloned into pCR2.1
vector and sequenced (Figure 11). Than it was cut out of plasmid by EcoR I.
Obtained fragment (position 51-558 in GenBank sequence, accession #
X69391) served as template in generation of radioactive probe.
                                                
∗ All bar diagrams are presenting mRNA levels quantified by PhosphorImager and normalized
to β-actin.
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Figure 11: Construction of TAXREB107-spesific template. Gene fragment was
amplified by RT-PCR, cloned into pCR 2.1 vector and sequenced. For the preparation
of radioactive probe insert was cut out by EcoR I.
3.2.6. Expression of TAXREB107 in granulocytes of PNH patients and patients
with related hematological diseases
Analysis of TAXREB107 gene expression in granulocytes of PNH patients
revealed clear overexpression for three out of seven cases. All of these
patients have been treated for aplastic anemia before the diagnosis of PNH. In
at least one of these three patients (T.C.) signs of dyserythropoiesis not
sufficient to diagnose MDS have been detected at the analysis of bone marrow
smear. We observed comparable overexpression level for patients with MPS.
In addition, overexpression of TAXREB107 has been found in a patient who
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developed MDS after SAA without cytogenetic abnormalities and in another
patient with AML after MDS whose bone marrow analysis revealed
continuous dysplastic granulo- and erythropoiesis after regeneration from
chemotherapy (Figure 12).
Figure 12: Expression of TAXREB107 in granulocytes.∗ For three out of seven PNH
patients clear overexpression of TAXREB107 has been observed. Comparable
overexpression is detected in some cases of myeloproliferative and myelodysplastic
diseases.
3.3. Overexpression of Egr-1 and altered cytokine level
In order to exclude that the observed differences are secondary to external
factors such as cytokines further investigations have been included. It has
been demonstrated in PNH patients that plasma concentrations of
endogenous hematopoiesis-regulatory cytokines (such as G-CSF) are
increased in comparison to normal donors (Nakakuma et al. 1997). Moreover,
                                                
∗ All bar diagrams are presenting mRNA levels quantified by PhosphorImager and normalized
to β-actin.
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the cytokine profiles of PNH patients are quite similar to those of patients
with aplastic anemia (AA) and myelodysplastic syndrome (MDS). As shown
previously, EGR-1 is rapidly and transiently expressed in response to G-CSF
and GM-CSF (Figure 13A). In order to exclude G-CSF as an external factor
leading to a differential expression of EGR-1 in granulocytes of PNH patients,
we tested its expression by Northern blot analysis in a patient receiving high
doses of G-CSF (2×5µg/kg) for mobilization of CD34+ cells. Application of
exogenous G-CSF did not lead to an overexpression of EGR-1 in the patients’
granulocytes (Figure 13B).
Figure 13: Overexpression of EGR-1 is not a result of altered levels of plasma
cytokines.∗ A: In order to address external influences such as cytokines leading to a
differential expression of EGR-1 in granulocytes, we analyzed the in vitro
stimulation of granulocytes with G-CSF resulting in a short-term up-regulation of
EGR-1. B: In contrast to in vitro stimulation, granulocytes obtained from patient,
receiving high doses of G-CSF for hematopoietic stem cell mobilization, did not
exhibit any increased EGR-1 expression. In addition, normal donor (A.Z.) with
leucocytosis due to sinubronchial infection (15 G/L) demonstrated also normal revel
of EGR-1 expression, comparable with value for that donor when healthy.
                                                
∗ All bar diagrams are presenting mRNA levels quantified by PhosphorImager and normalized
to β-actin.
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In order to exclude additional external factors present in the plasma of PNH
patients, we tested EGR-1 expression in granulocytes from normal donor after
incubation in patient’s plasma. This experiment has been performed for
different combinations of PNH patients and normal donors. Granulocytes
from a normal donor have been incubated for 3 different periods of time in
plasma of PNH patients compared to normal donors. 
As shown on Figure 14 no significant change in EGR-1 mRNA level was
observed in comparison to the control. In addition, the level of EGR-1 in
granulocytes obtained from normal donors with reactive leukocytosis due to
sinubronchial infection was not altered (Figure 13B, A.Z.). Although it can not
be completely excluded, our results favour the explanation that EGR-1
overexpression in PNH is rather due to intrinsic cellular factors and not
simply dependent from altered levels of plasma cytokines.
Figure 14: Incubation of normal granulocytes in plasma of PNH patients.
Granulocytes obtained from normal donor (J.S.) were incubated in plasma of PNH
patient (A.P.) and other normal donor (A.L.) for 3 different time periods. No
considerable changes in EGR-1 mRNA level∗ were observed. One representative out
of three different experiments is given. 
                                                
∗ All bar diagrams are presenting mRNA levels quantified by PhosphorImager and normalized
to β-actin.
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3.4. EGR-1: analysis of up-stream transcriptional factors
Early Growth Responce-1 factor (EGR-1) is a transcriptional factor regulating
expression of more than 30 genes, including growth factors and cytokines.
EGR-1 is rapidly and transiently induced by growth factors and differential
signals and is functionally involved in cell proliferation and differentiation.
EGR-1 expression can be induced via mitogen activated protein (MAP)
kinases. Several parallel MAP kinase signal transduction pathways have been
defined in mammalian cells. These pathways include the extracellular signal
regulated kinases (ERK), c-Jun N-terminal kinases (JNK, also known as
SAPK1) and p38 MAP kinases (SAPK2) (Rolli et al. 1999). In addition, EGR-1
expression can be regulated via JAK-STAT pathway (Tian et al. 1996) despite
the STAT5-binding site in direct proximity of EGR-1 gene promoter is not
reported. Figure 15 summarize the signal transduction pathway regulating
expression of EGR-1.
Thus, we hypothesized that overexpression of EGR-1 might be a result of up-
regulation of up-stream transcriptional factors. For this reason we
investigated the expression of serum response factor (SRF), STAT5a and
STAT5b as transcription factors regulating EGR-1. 
We compared expression level of SRF, STAT5a and STAT5b for PNH patients
with detected overexpression of EGR-1 and normal donors by Northern blot
hybridization analysis.
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Figure 15: Signal transduction pathways inducing expression of EGR-1 gene.
(according to (Tian et al. 1996; Watson et al. 1997; Khachigian and Collins 1998;
Smithgall 1998; Rolli et al. 1999; Coffer et al. 2000; Mora-Garcia and Sakamoto 2000)).
3.4.1. Gene-specific templates for up-stream transcriptional factors used in
Northern blot analysis
In order to study expression of SRF, STAT5a and STAT5b transcription factors
in PNH patients exhibited overexpression of EGR-1 we chose Northern blot
hybridization analysis. Cloned fragments of coding regions for these genes
were obtained from resources of RZPD as bacteria stocks. Every plasmid was
sequenced to confirm gene specificity of insert. Inserts were cut out by
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digestion with restriction enzymes (Figure 16), purified and used as template
for the radioactive probe synthesis.
Figure 16: Preparation of SRF, STAT5a and STAT5b specific templates for generation
of radioactive probes. Cloned fragments of genes were obtained from RZPD and
excised by restriction enzymes as indicated.
3.4.2. Analysis of expression of SRF, STAT5a and STAT5b as regulators of
EGR-1 transcription
In order to elucidate molecular bases of EGR-1 overexpression in PNH we
compared expression level of SRF, STAT5a and STAT5b in granulocytes of
PNH patients and normal donor by Northern blot hybridization analysis. No
significant difference in expression was observed for any of them.
Representative Northern blot probed for STAT5b is shown on the Figure 17.
Therefore, we conclude that EGR-1 overexpression in PNH is not a
consequence of possible overexpression of up-stream transcriptional factors.
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Figure 17: Analysis of up-stream transcriptional factors for EGR-1∗. Shown
representative Northern blot probed for STAT5b. No change in expression
level of STAT5b as well as STAT5a and SRF detected.
3.5. Analysis of EGR-1 chromosomal organization, gene and transcript
structures
We have shown that Early Growth Responce-1 factor (EGR-1) is
overexpressed in GPI-deficient granulocytes of all PNH patients studied so
far.
EGR-1 belongs to the class of early response genes and can be rapidly and
transiently expressed in response to different stimuli. We demonstrated that
overexpression of EGR-1 in PNH is not a result of altered plasma cytokine
level (Results, 3.3). In addition, we did not observed any changes in
expression level of EGR-1 up-stream trancriptional factors (factors regulating
EGR-1 transcription) for PNH patients in comparison to normals (Results,
3.4.).
                                                
∗ All bar diagrams are presenting mRNA levels quantified by PhosphorImager and normalized
to β-actin.
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Therefore, analysis of EGR-1 chromosomal organization (FISH experiments),
EGR-1 promoter structure and structure of the gene coding region was
performed in order to analyze EGR-1 overexpression in PNH.
3.5.1. EGR-1 promoter studies 
In order to analyze the primary structure of EGR-1 promoter (Figure 18) we
constructed plasmids harboring the EGR-1 promoter fragment spanning
nucleotide –674 to +12. We performed 2 parallel PCR reaction for every PNH
patient and normal donor and sequenced at least 3 different plasmids for
every cloned PCR fragment. DNA sequencing analysis of both DNA strands
was performed as described.
Obtained sequences were analyzed using GeneRunner software and searched
against GenBank, dbEST and SwissProt databases through the BLAST server.
We detected that EGR-1 promotor sequence for all PNH patients studied is
identical to the corresponding region of normal donors and to the published
complete nucleotide sequence.
3.5.2. EGR-1 coding region studies
The human EGR-1 gene is composed of two exons and one intron, spanning
approximately 3,6 kb (Sakamoto et al. 1991). EGR-1 belongs to the EGR family
of zinc-finger transcriptional factors. EGR-1 protein is 544 aa long (accession #
P18146) and has three zinc-finger C2H2-type domains and one transactivation
domain (Figure 19).
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                                                                           Sp1                                           cAMP RE
CGGTTCGCTCTCACGGTCCCTGAGGTGGGCGGGCGGGCCCTGGATGACAGCGATAGAACC
1                     10                        20                       30                        40                        50                       60
                 TPA RE                      EBS
CCGGCCCGACTCGCCCTCGCCCCCGCTCTGGGTCTGGGCTTCCCCAGCCTAGTTCACGCC
61                    70                       80                      90                      100                    110                      120
                                                                                                                                                    Sp1
TAGGAGCCGCCTGAGCAGCCGCGCGCCCAGCGCCACACGCCACGAGCCCTCCCCGCCTGG
121                130                    140                       150                      160                     170                      180
GCGTCCCCGGATCCCGCGAGCGCTCGGGCTCCCGGCTTGGAACCAGGGAGGAGGGAGGGA
181               190                      200                     210                      220                     230                        240
                                                                                                      SRE5
GCGAGGGAGCAACCAGCTGCGGACCCGGAAATGCCATATAAGAAGCAGGAAGGATCCCCC
241                250                     260                       270                     280                       290                      300
                     SRE4                                                          SRE3
GCCGGAACAACCCTTATTTGGGCAGCACCTTATTTGGAGTGGCCCGATATGGCCCGGCCG
301                310                    320                     330                     340                     350                       360
CTTCCGGCTCTGGGAGGAGGGAAGAAGGCGGAGGGAGGGGCAACGCGGGAACTCCGGAGC
361              370                       380                       390                       400                      410                      420
TGCGCGGGTCCCGGAGGCCCCGGCGGCGGCTAGAGCTCTAGGCTTCCCCGAAGCCTGGGC
421                430                      440                      450                     460                     470                     480
GCCTGGGATGCGGGCGCGGGCGCGGGCCCTAGGGTGCAGGATGGAGGTGCCGGGCGCTGT
481                490                      500                      510                      520                      530                     540
                                     cAMP RE                                                                   SRE2               SRE1
CGGATGGGGGGCTTCACGTCACTCCGGGTCCTCCCGGCCGGTCCTGCCATATTAGGGCTTC
541                550                     560                      570                     580                    590                        601
CTGCTTCCCATATATGGCCATGTACGTCACGACGGAGGCGGACCCGTGCCGTTCCAGAC
602               610                      620                    630                       640                      650                 660
              TATA
CCTTCAAATAGAGGCGGATCCGGGGAGTCGCGAGAGATCCAGC
661               670                      680                       690                     700
Figure 18: Complete nucleotide sequence of the human EGR-1 promoter. Regulatory
sequence elements are boxed (according to (Schwachtgen et al. 2000)). Sp1 = Sp1
binding site; cAMP RE = cyclic AMP response element; TPA PE = 12-O-
Tetradecanoyl phorbol 13-acetate response element; EBS = EGR-1 binding site; SRE =
serum response element; TATA = TATA box. (GeneBank accession number
AJ245926).
It is important to note that the transactivation domain of EGR-1 gene harbors
six trinucleotide AGC repeats at two regions in nucleotide positions 454 to 471
and 505 to 522 (AGC6/33/6) according to GenBank NM_001964 (Gashler and
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Sukhatme 1995). The transactivation domain activates transcription 100-fold.
Mutations in the transactivation domain may abrogate the EGR-1
transcriptional activity.
We analyzed the primary structure of EGR-1 gene coding region. For that
reason several fragments overlapping the ORF were amplified by RT-PCR
and PCR from genomic DNA and sequenced (described in detail in Methods).
Figure 19: EGR-1 as a transcriptional factor. A: Domains of EGR-1 protein are shown.
Three zinc-fingers DNA-binding domains are labeled accordingly (shown in black).
The transactivation domain is shown in gray. B: EGR-1 is shown binding to the
canonical EGR response element (RE) upstream of hypothetical target gene. Each
zinc-finger (black circle) binds to a three-nucleotide site in an antiparallel
configuration with zinc-finger I binding to the 3’-most nucleotide triplet and zinc-
finger III binds to the 5’-most nucleotide triplet.
GCG   GGG   GCG
III       II        I
T
       Zinc fingers
   I            II          III
B
A
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We amplified and sequenced the EGR-1 coding region from both genomic
DNA and RNA obtained from four PNH patients with EGR-1 overexpression.
We detected no significant changes or earlier described mutations within the
primary structure of the coding region compared to EGR-1 GeneBank
sequences XM_004063 for mRNA and NM_001964 for genomic DNA.
However, for every patient among with normal clones we found some clones
(approximately 1/3 out of all analyzed clones containing the corresponding
region) with single nucleotide changes (shown in the Table 3).
Patient RCR fragment clone comparison to GeneBank XM_004063
A.P. sense+5038r
cDNA
1b position 1559 T→C
position 1561 T→C
W.E. sense+5038r
genomic
4b position 1354 A→G 
(zinc-finger domain I)
J.S. sense+5038r
cDNA
5b position 1583 T→C
J.A. sense+5038r
genomic
8b position 1522 A→G 
(zinc-finger domain III)
Table 3: Point mutations in EGR-1 coding region found in PNH patients with EGR-1
overexpression.
All detected molecular changes are located within the part of the coding
region encoding for zinc fingers. In addition, two of detected point mutation
(patients W.E. and J.A.) are located directly within zinc fingers I and III
respectively. The second histidine in the consensus structure of C2H2 zinc-
finger (Tyr/Phe−X−Cys−X2-4−Cys−X3−Phe/Tyr−X5−Leu−X2−His−X3-4−His) is
affected in both cases and exchanged to arginine. Such molecular change
might lead to a significant alteration of EGR-1 protein function as a
transcriptional factor due to alteration of zinc-finger affinity to DNA.
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However, this assumption has to be verified on a larger series of patients and
on experiments providing inside into the effects on cellular biology due to
mutated EGR-1.
3.5.3. FISH analysis
In order to study chromosomal organization of EGR-1 and detect possible
gene amplification or loss of heterozygosity we performed FISH analysis with
molecular probe to EGR-1 (5q31) loci for granulocytes obtained from blood of
normal controls and PNH patients. We modified the standard technique by
choosing granulocytes instead of whole blood for analysis because of their up
to 100% GPI-deficiency in PNH. Thus, it allowed us to directly compare the
normal cells and PNH-clone.
For the FISH analysis we used probe LSI 5q EGR1 SO/ D5S23 SG obtained
from Vysis, Inc. This FISH probe is generally used to determine the presence,
amplification or absence of EGR-1 loci (5q31 band) and appears as an orange-
red signal. As an internal control locus D5S23 (15p15.2 band) was used which
appears as a green signal. The hybridized probe fluoresces with moderate to
bright intensity both in interphase nuclei and on metaphase chromosomes. In
the nuclei of normal cells, the probe generally appears as four distinct signals
(two red and two green). Occasionally, the probe may appear as five or six
signals, depending upon the condensation of the DNA and the relative
distances between chromatids. The signals may also appear diffuse or split. In
normal metaphase spreads, the probe may appear as two to four signals on
each chromosome 5.
We analyzed granulocytes of three PNH patients with observed
overexpression of EGR-1 and compared them to normal granulocytes. The
results of fluorescent microscopy are presented on the Figure 20. Two red
(EGR-1 loci, 5q31) and two green (control, 15p15.2) signals were clearly
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detectable in the vast majority of nuclei of either normal or PNH
granulocytes. In addition, for every sample we counted signals of 200 nuclei.
Counting data are presented in the Table 4. Table 4 and Figure 20 indicate that
PNH and normal samples were visually undistinguishable from each other
and 99% of cells exhibit counts characteristic for normal cells. Therefore, it can
be concluded that EGR-1 overexpression in granulocytes of PNH patients is
not a consequence of any chromosomal aberration within the EGR-1 loci such
as gene amplification. 
Sample
# cells, 0 dots
red / green
# cells, 1 dot
red / green
# cells, 2 dots
red / green
# cells, 3 dots
red / green
# cells, >3 dots
red / green
Normal
(A)
0 / 0 4 / 3 195 / 196 1 / 0 0 / 1
PNH (B) 1 / 0 5 / 4 194 / 195 0 / 1 0 / 0
PNH (C) 0 / 0 2 / 1 196 / 194 2 / 4 1 / 1
PNH (D) 0 / 0 1 / 0 199 / 198 0 / 2 0 / 0
Table 4: FISH analysis of granulocytes of PNH patients and normal control.
Counting data for 200 nuclei are presented. Healthy control and PNH patients are
indicated A, B, C and D corresponding to images on the Figure 20. 
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Figure 20: FISH molecular analysis of normal and PNH granulocytes. Granulocytes
were isolated from fresh whole blood, fixed by methanol/acetic acid and hybridized
with LSI 5q EGR-1 SO / D5S23 SG dual color DNA probe. Red signals are
corresponding to the band 5q31, EGR-1 loci; green signals − 5p15.2, locus D5S23.
Panel A: normal donor (J.S.), panels B, C, D: PNH patients (J.A., A.P. and W.E.
respectively). 
C D
A B
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4. Discussion
4.1. Clonal expansion in PNH: a consequence of immune selection or of
additional gene alterations?
The pathophysiology leading to the expansion of GPI-deficient clones within
the bone marrow of PNH or PNH/aplasia patients is still a matter of
controversial discussions (Dunn et al. 1999). Especially, the frequent
appearance of expanded GPI-deficient bone marrow cells in aplastic anemia
patients has led to the hypothesis that GPI-deficient cells as a result of clonal
expansion would escape the suppressive action of the immune system (Dunn
et al. 1999). This is further supported by the observation that in some PNH
patients more than one GPI-deficient clone is present (Bessler et al. 1994; Nafa
et al. 1995). However, there are no investigations reported about the size of
each clone contributing to the GPI-deficient cell fraction so far. If all these
clones would exhibit an equal size, an absolute growth advantage of one
clone dominating the bone marrow would be unlikely. However, if there
would be one dominating and several minute size clones as described in
normals (Araten et al. 1999) this would not rule out such an absolute growth
advantage. GPI-deficient cells exhibit the same susceptibility to the cytotoxic
action of allogeneic T-cells as normal cells do (Karadimitris et al. 2000). Thus,
a direct recognition of GPI-linked proteins or GPI-anchor molecules presented
at the surface of hematopoietic stem cells by immunological effector cells
needs to be anticipated (Porcelli and Modlin 1999). On the other hand, cells of
virtually all tissues express GPI-anchors. Therefore, it would be necessary to
anticipate that the cytotoxic reaction could distinguish between hematopoietic
and non-hematopoietic cells because otherwise the resulting tissue damage
would not be compatible with life. In addition, such an organ destruction is
not present in the list of clinical features of PNH or AA. It has been proposed
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that the autoimmune attack restricted to HSC could be associated with an
expansion of cytotoxic T/NK cells recognizing GPI-anchor structures in the
context of CD1d molecules (Schofield et al. 1999; Taniguchi and Nakayama ).
Such clones have been found in other autoimmune diseases, but not in PNH
or AA patients so far. An alternative explanation could be that GPI-linked
surface proteins such as ULBP’s (cytomegalovirus glycoprotein UL16 binding
proteins) (Cosman et al. 2001) might directly interfere with activating
receptors (NKG2D) on NK cells (Pende et al. 2001). The expression pattern of
these molecules is unknown to the date. Should they turn out to be HSC-
specific, the restriction of the autoimmune reaction to HSC could be possibly
explained.
As an alternative to the immune escape it was suggested that GPI-deficiency
itself leads to an increased resistance to apoptosis (Brodsky et al. 1997). An
increased rate of apoptosis has been observed in patients with aplastic anemia
or myelodysplastic syndrome (Heaney and Golde 1999; Killick et al. 2000;
Novitzky et al. 2000). If GPI-deficient cells would exhibit such a resistance due
to only the absence of GPI-linked surface molecules, clonal dominance of the
GPI-deficient clone would result in the context of AA or MDS. However, this
observation could not be reproduced by other groups (Ware et al. 1998;
Bastisch et al. 2000). Therefore, it has to be anticipated that resistance to
apoptosis observed in GPI-deficient cells of PNH patients would be a result of
changes distinct from the deficient surface expression of GPI-linked proteins. 
GPI-deficient cells present in PNH exhibit an increased genetic instability,
which is also observed in related diseases with defined genetic aberrations
such as MDS (Hattori et al. 1997; Purow et al. 1999).
Therefore, we postulated that there are such additional alterations affecting
genes regulating cellular proliferation and altered growth of GPI-deficient
cells and, thus, responsible for clonal expansion in PNH.
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4.2. Differential gene expression in PNH
In order to elucidate the molecular basis of clonal expansion in PNH we
identified genes differentially expressed in normal and GPI-deficient cells. To
enhance the productivity of a such analysis we have employed combination
of two divergent approaches. cDNA Atlas array hybridization let us to
investigate expression of genes already reported to play a role in human
hematopoiesis and belonged to different classes – transcription regulators,
cytokines and cell surface markers. RNA fingerprinting is based on PCR-
mediated differential screening and has a significant advantage that it can be
performed starting with only an amount of RNA as small as 0,1 µg. Moreover,
due to an amplification step it has a different sensitivity and therefore
allowed us to isolate diverse set of genes comparing to the Atlas cDNA array
hybridization method.
We could demonstrate that GPI-positive and GPI-negative cells of the same
PNH patient have different gene expression profiles. This could be explained
by the observation of increased genetic instability ratio in GPI-deficient cells
of PNH-patients reported recently (Hattori et al. 1997; Purow et al. 1999).
Thus, a genetic instability would be the basis for molecular changes leading to
an altered gene expression pattern.
We have chosen 2 candidates out of 26 differentially expressed genes for
further study according to their pronounced variation in expression level and
their previously described role in regulation of hematopoiesis.
4.3. TAX-responsive enhancer element binding protein 107 (TAXREB107)
TAXREB107 (TAX-responsive enhancer element binding protein 107) has
been described as a protein mediating DNA binding for HTLV I trans-
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activator of transcription (tax) for its own viral promoter (Sodroski et al.
1984), and also for some promoters of cellular genes such as IL-2, IL-2Rα, GM-
CSF and c-fos (Nagata et al. 1989). TAXREB107 has a leucine zipper motif and
binds specifically to the C-domain of tax-responsive enhancer element, which
has some similarity with the cAMP response element (CRE). However, the
function of TAXREB107 in uninfected cells has not yet been completely
clarified. Nevertheless, it appears to be upregulated upon the action of
erythropoetin (Li et al. 1999). 
Dyserythropoiesis has been described in a series of PNH (Iwanaga et al. 1998;
Dunn et al. 1999). In the patients analyzed here, maturation disturbances have
been present in those patients providing an increased level of TAXREB107
transcription. These results need to be verified in a larger series of PNH or AA
patients. However, TAXREB107 could be a candidate gene indicating
additional changes such as an increased cycling stress within erythroid
progenitors.
4.4. Early Growth Response-1 Factor (EGR-1)
Early growth response gene EGR-1 (Varnum et al. 1989) (also known as Krox
24, Tis 8, zif-268, G0S30 and NFGI-A) is a ubiquitously expressed zinc finger
transcription factor (59kDa) (Cao et al. 1990) which can act to either positively
or negatively regulate gene transcription (Gashler et al. 1993; Lin and Leonard
1997). Its ambivalent effect on regulation of hematopoiesis has been described
(Varnum et al. 1989; Nguyen et al. 1993; Dinkel et al. 1998). EGR-1 was first
identified as putative G0/G1 switch regulatory gene in human blood
lymphocyte cultures and named G0S30 (Forsdyke 1985). It has been
demonstrated to be a critical upstream mediator of proliferation (Perez-
Castillo et al. 1993), differentiation (Nguyen et al. 1993; Dinkel et al. 1998), and
apoptosis (Muthukkumar et al. 1997; Nair et al. 1997). In conditions of stress,
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EGR-1 acts as an antiapoptotic gene and counteracts p53-dependent apoptosis
(de Belle et al. 1999). Moreover, physical interaction between p53 and EGR-1
proteins has been recently reported (Liu et al. 2001). In addition, the EGR-1
gene product has decreased expression and activity during cellular
senescence (Meyyappan et al. 1999).
In our investigations, we have found EGR-1 to be strongly up-regulated in all
studied cases of PNH and in some cases of myeloproliferative and
myelodysplastic diseases. MDS and MPS are generally assumed as clonal
diseases driven by molecular changes within their activation gene program
(Killick et al. 2000). Furthermore, there are certain similarities and some
overlap between PNH and MDS (Young and Maciejewski 2000). We assume
that differential regulation of EGR-1 as a gene, playing a role in the regulation
of differentiation, proliferation, apoptosis and regulation of the cell cycle,
could be associated with expansion of GPI-deficient clones in PNH. In our
experiments we have also shown that overexression of EGR-1 in PNH is not
due to extrinsic factors such as increased level of cytokines but is rather
caused by intracellular changes.
To further investigate the molecular basis behind upregulated EGR-1 gene
expression we analyzed EGR-1 chromosomal and gene organization. We
detected no mutations whithin the promoter region of EGR-1 gene and no
molecular aberrations in ERG-1 loci according to results of FISH analysis.
However, when sequencing the EGR-1 coding region, we detected some
clones with point mutations despite the majority of analyzed clones had the
sequence identical to normal. Interestingly, all detected mutations are located
in the region encoding for zinc-finger domains. It is well known that EGR-1 is
a zinc-finger transcriptional factor. Therefore, mutations in such a region
might strongly influence the protein function. 
However, it cannot be concluded strait forward that EGR-1 is connected
directly with the growth advantage of the GPI-deficient hematopoietic cells.
Moreover, there is even no definite information, which expression level of
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EGR-1 would be sufficient for clonal expansion and which level would be
deleterious for the function of hematopoietic stem or progenitor cells
(Krishnaraju et al. 1998). The statement of a genetic basis such as EGR-1
overexpression in clonal dominance is further complicated by the observation
that the proportion of GPI-deficient cells in PNH can be stable over a
prolonged period of time (Schrezenmeier et al. 2000; Maciejewski et al. 2001).
It was recently reported that EGR-1 mRNA level is expressed at a significantly
higher level in cancer cells than in normal tissue (Eid et al. 1998). In addition,
the structure of the EGR-1 gene implies that it may particularly be subject to
microsatellite instability because of nucleotide repeats at three exon regions
(Gashler and Sukhatme 1995). It appears to be very interesting taking into
account our findings of point mutations in EGR-1 gene region encoding C2H2
zinc-fingers domains. For two patients the second histidine coordinating zinc
ion in zinc-fingers structure is replaced by arginine. Such molecular
alterations would shift the affinity of zinc-finger to DNA and might lead to
significant changes in EGR-1 transcriptional factor function. This could even
be responsible for the revealed overexpression of EGR-1 in PNH due to the
presence of an EGR-1 binding site in promoter region of EGR-1 gene. In
addition, the functional role of EGR-1 within the cell favors the hypothesis
that any changes in EGR-1 gene expression or activity might be a primary
alteration that occurred in PNH cells.
It has recently been reported that EGR-1 directs murine myelopoiesis to the
monocytic lineage on expense of self-renewal of pluripotent hematopoietic
stem cells (Krishnaraju et al. 1998; Krishnaraju et al. 2001). This is of particular
interest because of relative monocytosis indicates an ongoing clonal evolution
such as PNH or MDS in the course of aplastic anemia (Nissen et al. 2000).
These observations support our hypothesis that differential regulation of
EGR-1 in hematopoietic stem cells could provide conditions for clonal
expansion such as in PNH. However, the recently described increased genetic
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instability (Hattori et al. 1997) may possibly result in more than one alteration
of gene expression which could be responsible for clonal expansion in PNH.
4.5. Molecular changes in PNH
In this work, we found that molecular changes additional to PIG-A gene
mutations are presented in PNH. Moreover, these gene expression alterations
can be detected in hematological diseases with a related pathogenesis such as
aplastic anemia, myelodysplastic and myeloproliferative syndromes. In
addition, the research group of T. Kinoshita recently reported mutation in a
HMGI-C/HMGA2 transcriptional factor (Inoue et al. 2001), a second genetic
mutation confined to GPI-deficient cells in PNH, which in fact favors the
hypothesis that clonal expansion in PNH is driven by additional molecular
alterations. 
Since underlying genetic defects leading to the upregulation of EGR-1 and
TAXREB107 have not yet been uncovered, it might also be possible that the
observed expression changes result from genetic alterations located within
direct proximity of both genes. However, our results imply that the observed
altered regulation is not a result of extracellular factors but merely of an
altered genetic program possibly due to a clonal transformation process.
Taken together, these results indicate, that in clonal cells from PNH patients
molecular events distinct from regulation by the immune system or resistance
to apoptosis are presented. The observed differential gene expression or
mutations whithin functional domains of genes regulating cellular growth
could be responsible for clonal expansion of GPI-deficient cells in patients
with PNH. Further studies will be required to confirm genetic alteration at a
molecular level. This could be the basis for establishing more sensitive
diagnostic tests in order to further understand and distinguish the
pathophysiology of clonal disease such as PNH.
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